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Environmental factors are key determinants of human health. 
























POPULAR SCIENCE SUMMARY OF THE THESIS 
We are in the midst of the silent pandemic of antibiotic resistance that continues to grow around 
the world. If no urgent actions are taken, antibiotic resistance will have a devastating impact. 
The reduced efficiency of therapeutic antibiotic use can lead to increased hospitalisations for 
patient infections caused by antibiotic-resistant bacteria, and to treatment failure and mortality. 
Deaths from antimicrobial-resistant infections will increase from the current 700,000 to 10 
million annually by 2050 and cost up to USD 100 trillion. In addition, concerns are growing 
about the impact of antibiotic resistance on the environment. Antibiotics enter the environment 
through different sources such as pharmaceutical plants, hospitals, and municipals. 
Accordingly, antibiotic residues have been detected in the environment such as drinking water, 
vegetables, river water, ground water, and wastewater treatment plants. Antibiotic residues are 
likely to lead to the development of antibiotic resistant bacteria in the environment. Further, 
there is the potential risk of antibiotic residues via drinking water or food consumption 
disrupting our gut flora, inducing the emergence of resistance, and also posing toxic effects. 
Our understanding of the occurrence of antibiotic resistance in the environment, and its 
potential risk to human health, is limited. This must be further explored to protect human health 
and the environment. The studies included in this thesis therefore examined the environmental 
contamination of antibiotic residues and resistance, assessed their risk to the environment and 
human health in the Western Pacific Region (WPR) and South-East Asia Region (SEAR) of 
the World Health Organization, particularly China and India, and developed methods for the 
prioritisation of antibiotics for environmental and health policy. 
Antibiotic residues and antibiotic resistance were present in various environmental 
compartments of the WPR and SEAR, in particular China and India. Antibiotics were observed 
to pose resistance risk in the wastewater of Shandong province in China. Antibiotic residues 
and antibiotic resistant bacteria in the water of the Kshipra river of India were associated with 
different seasons, sites, and water quality parameters over a 3-year period. The concentration 
levels of some antibiotics were estimated to pose an environmental risk for the development of 
antibiotic resistance in the environment of the WPR, the SEAR, China, and India. Antibiotics 
appear to pose a resistance risk to human health from environmental exposure via drinking 
water. A list of priority antibiotics based on their environmental and human health risks of 
resistance, toxicity, and ecotoxicity in all types of aquatic environmental compartments was 
developed. Ciprofloxacin posed the greatest risk. The highest risks of antibiotic residues were 
observed in wastewater and wastewater treatment plants’ influents and effluents. Wastewater 
and wastewater treatment plants act as a major source and primary pathway for environmental 
contamination by antibiotic residues and antibiotic resistance in these regions. 
The knowledge generated in this thesis can help decision-makers to undertake well-directed 
actions towards monitoring and mitigating antibiotic residues and antibiotic resistance. 
Antibiotic residues can be targeted for remediation, wherever there appears to be a high risk of 
development of resistance within the environments of the WPR, the SEAR, China, and India. 
The outcome from the proposed approach can be used to develop targeted policies which 
 
 
would prevent and minimise the environmental and human health risks of antibiotic residues, 
and to help focus research efforts. 
As a whole, the emergence of antibiotic residues and antibiotic resistance in the environment 
caused by human actions and inactions show how their defined and measurable risks can 
influence our health and the environment. This has to stop, with us tackling antibiotic 












Background: Antibiotic resistance is a global health crisis and a serious threat to progress in 
achieving the Sustainable Development Goals. This requires a One Health response that 
recognises the link between human and animal health and the environment. While within One 
Health, human and animal health feature prominently in terms of research and implementation, 
the efforts to tackle antibiotic resistance in the environment lag far behind in attention, evidence 
base, and political commitment. The knowledge of the emergence of antibiotic residues and 
antibiotic resistance in the environment, and the magnitude of the human health risk posed by 
it, remain limited. Various anthropogenic sources such as the pharmaceutical industry, hospital, 
and municipal wastewater release antibiotic residues into the environment. To define the risks 
to the environment and human health and to inform policy, there is a particular need to assess 
antibiotic concentrations in the environment at which resistance might develop and pose a 
health threat. 
Aim: To assess the potential environmental and human health risks of exposure to antibiotic 
residues and antibiotic resistance in various environmental compartments of the Western 
Pacific Region (WPR) and South-East Asia Region (SEAR) of the World Health Organization, 
particularly China and India, and to develop methods for the prioritisation of antibiotics to 
deal with aspects of their resistance and the toxicity risks on human health and various aquatic 
environmental compartments. 
Methods: In Study I, quantitative methods to determine antibiotic concentrations in various 
environmental compartments in rural Shandong province in China were used, and risk 
assessment methods to characterise environmental and health risks of antibiotic residues were 
performed. In study II, quantitative methods to investigate antibiotic residue levels and water 
quality in the river water samples from the Kshipra river in India during different seasons, 
and sampling sites over a 3-year period were applied, and microbiological and molecular 
methods to test antibiotic resistant Escherichia coli (E. coli) and antibiotic resistance genes 
were used. In study III, I conducted a systematic review of the literature (WPR (n=218), 
SEAR (n=22), China (n=168), and India (n=15)) published between 2006 and 2019, to 
investigate the occurrence and concentration of the reported antibiotic residues in various 
aquatic environmental compartments of the WPR and SEAR. I also used risk assessment 
methods including Probabilistic Environmental Hazard Assessments, to assess antibiotic 
exposures in various aquatic environmental compartments for concentrations of antibiotic 
residues that are above Predicted No Effect Concentrations for resistance development. In 
Study IV, I developed an integrated environment–human risk approach for a quantitative 
environmental (resistance and ecotoxicity) and human health (resistance and toxicity) risk 
assessment of antibiotic residues and a prioritisation system thereof. I propose a risk-based 
approach; the approach combines data on the exposure, toxicity, resistance, and chemical 
structure of antibiotics with Probabilistic Environmental Hazard Assessments and a 
Threshold of Toxicological Concern. The utility of the approach and the system was 





Findings: Antibiotic residues were present in various environmental compartments of the 
WPR, the SEAR, China, and India (Study I, Study II, and Study III). The concentration levels 
of enrofloxacin, levofloxacin, and ciprofloxacin in wastewater were estimated to pose 
environmental risks for the development of antibiotic resistant bacteria in the environment of 
Shandong province, in China (Study I). Antibiotic resistant E. coli were present in the water 
and sediment of the Kshipra river in India and showed significant seasonal and spatial 
variations over a 3-year period, and had varying associations with measured water quality 
parameters (Study II). In the WPR, 92 antibiotics were detected, and in the SEAR, 45 
antibiotics were detected. Values of predicted threshold concentrations corresponding to 
different centiles for environmental exposure distributions of the maximum measured 
environmental concentrations of antibiotic residues, and the likelihood of exceedances of 
antibiotic Predicted No Effect Concentrations for resistance development of the WPR, the 
SEAR, China, and India were indicated (Study III). The highest environmental risks of 
antibiotic residues were observed in wastewater, and wastewater treatment plants’ influents 
and effluents (up to 100%) (Study III). Antibiotic residues appear to pose an appreciable 
human health risk from environmental exposure via drinking water of the WPR and China, 
and the highest risk was observed for ciprofloxacin (62.5%) (Study III). A list of priority 
antibiotics from different classes for China was developed by ranking antibiotics in 
descending order, based on their a) overall risk, b) resistance risk on environment, c) 
ecotoxicity risk, d) overall environmental risk, e) resistance risk on human health, f) toxicity 
risk on human health, and g) overall human health risk. Ciprofloxacin posed the greatest risk 
(Study IV). 
Conclusions: A novel assessment of the health risk due to the antibiotic residues in the aquatic 
environment of the WPR, the SEAR, China, and India were presented in this thesis. Antibiotic 
residues and antibiotic resistance were ubiquitous. There is evidence that residual 
concentrations of some antibiotics exceeded the thresholds for the development of resistance 
in various proportions of exposure in various aquatic environments of the WPR, the SEAR, 
China, and India, and posed an ecotoxicity effect. Wastewater and wastewater treatment 
plants serve as a hot spot for the development of antibiotic resistance in these regions. 
Antibiotic residues appear to pose an appreciable resistance and toxicity risk to human health 
from environmental exposure via drinking water. The emergence of antibiotic residues and 
resistance in drinking water further emphasises the need to place these threats to humans in 
the perspectives of environmental and health policy. These findings can help decision-makers 
to derive special risk reduction measures and focus mitigations towards priority antibiotics and 
high-risk sites, to decide the desired level of protection based on the proportions of exposure 
impacted, to implement eco-pharmacovigilance, and to help focus research efforts. This has 
the potential to assist decision-makers in efficiently allocating resources, which is especially 
vital for resource-poor settings e.g., in the WPR and SEAR. 
Key words: antibiotic residues, antibiotic resistance, environment, human health, integrated 
quantitative risk assessment, prioritisation system, health policy, eco-pharmacovigilance. 
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Antimicrobial Substance of natural, semi-synthetic, or synthetic origin that in 
in vivo concentrations kills or inhibits the growth of 
microorganisms, such as bacteria, fungi, viruses, and 
protozoans. Antimicrobials with activity against bacteria are 









1.1 ANTIBIOTIC RESISTANCE IS A GLOBAL CRISIS 
Antibiotic resistance is a global health crisis of the 21st century and a serious threat to progress 
in achieving the Sustainable Development Goals. Antibiotics are important tools for preventing 
and treating bacterial infectious diseases in humans, animals, aquaculture, and agriculture. 
However, the emergence of resistance to these medicines threatens a century of progress in 
human health. Common infections have become resistant to several antibiotics that have been 
used in treating them, and lifesaving medical procedures and treatments are risky to perform. At 
the same time, there is a lack of scientific innovation resulting in part from market failure, with 
too few new antibiotics, diagnostic tools, vaccines, and alternatives to antibiotics in the research 
and development pipeline (1, 2). 
Unless the world acts urgently, antibiotic resistance will have a devastating impact. The reduced 
efficiency of therapeutic antibiotic use can lead to increased hospitalisations for patient infections 
caused by antibiotic-resistant bacteria, and to treatment failure and mortality. Antimicrobial-
resistant infections have already caused at least 700,000 global deaths annually, and this figure 
could increase to 10 million by 2050 if no action is taken. The economic consequences of 
uncontrolled antimicrobial resistance would also be disastrous. It has been estimated that it would 
cost up to USD 100 trillion globally by 2050, and millions of people could be forced into extreme 
poverty, mainly in low- and middle-income countries (LMICs). As antibiotic resistant pathogens 
spread, food security—including global trade in livestock, food, and feed—would also be 
increasingly jeopardised. In addition, concerns are growing about the impact of antibiotic 
resistance on animal health, environment, water and sanitation, social development, business and 
trade, and travel and tourism. Antibiotic resistance does not recognise geographical or ecological 
borders, impacting many countries worldwide (3, 4). 
1.2 A ONE HEALTH RESPONSE TO ADDRESSING ANTIBIOTIC RESISTANCE 
Addressing the complex global challenge of antibiotic resistance on multiple fronts requires an 
integrated and holistic One Health response that considers the connections between human and 
animal health and the environment (5, 6). One Health is the collaborative effort of multiple 
disciplines—working locally, nationally and globally—to attain optimal health of people, 
animals, and the environment. Antibiotic resistance has been described as the “quintessential One 
Health issue” as it exists in all three sectors. The World Health Organization (WHO) Global 
Action Plan on Antimicrobial Resistance (7), declaration from the 2016 high-level meeting on 
antimicrobial resistance at the United Nations General Assembly (8) and the Food and 
Agriculture Organisation of the United Nations (FAO)/the World Organisation for animal health 
(OIE)/the WHO (9) —all of which emphasise the importance of a One Health approach to 





1.3 THE CURRENT GLOBAL RESPONSE TO ANTIBIOTIC RESISTANCE IN THE 
ENVIRONMENT IS INADEQUATE 
While the impact of antibiotic resistance on human health has received considerable attention, 
political commitment and stakeholder involvement in these areas are still inadequate nationally 
and globally. Antibiotic resistance in animals requires more attention and political commitment, 
while efforts in tackling antibiotic resistance in the environment lag far behind in attention, 
evidence base, advocacy, and political commitment. Our limited understanding of the relation 
between the resistance in humans, animals, and the environment might be responsible for the 
lack of any significant environmental focus in existing policies and Antibiotic Resistance Action 
Plans. This might hinder the ability of the environmental decision-makers and regulators from 
delivering environmental and human health protection from antibiotic residues and antibiotic 
resistance.  Without consideration of all the drivers, pathways, and impact of antibiotic residues 
and antibiotic resistance in the environment, Antimicrobial Resistance Action Plans are 
insufficient and at risk of not achieving the desired goals of tackling antibiotic resistance and 
ensuring and improving the efficacy of the existing and future antibiotics (10–12).  
1.4 THE DRIVERS OF ANTIBIOTIC RESISTANCE 
Although the development of antibiotic resistance is a natural phenomenon for bacteria, the 
emergence of antibiotic resistance in human pathogens is a recent event in evolutionary terms, 
which has occurred after the introduction of such medicines as antibacterial agents (13). The use 
of antibiotics accelerated the emergence of antibiotic-resistant bacteria, reducing their therapeutic 
potential against human and animal pathogens (14). As such, the current problem of antibiotic 
resistance should be considered as an example of anthropogenic-driven evolution. 
Antibiotics have been extensively used for therapeutic and non-therapeutic purposes in humans, 
animals, aquaculture, and agriculture. Veterinary antibiotics have been used in the prevention 
and treatment of infectious diseases in animals, but they are gradually added as prophylactics and 
growth promoters, which currently far exceeds their use as animal therapeutics (15). Although 
bans on the use of antibiotics as growth promoters have been introduced in many countries such 
as China, how these policies are implemented, monitored, and enforced remain to be seen. Global 
antibiotic use in humans is projected to increase by 200% by 2030 (16). This increase is expected 
to be faster in LMICs as their economies grow and access to health services improves. The 
estimated global antimicrobial consumption in food animal production is projected to rise by 
67% by 2030. For LMICs such as China and India, the increase in antimicrobial consumption 
will be 99%. The use of antibiotics to routinely prevent disease and promote growth in healthy 
animals without appropriate significance and in the absence of good agriculture and practices to 
prevent infectious diseases in animals are further contributing to the development and spread of 
antibiotic resistance (17). 
The drivers of antibiotics use in human and veterinary medicine, crop protection, and aquaculture 
– especially in many LMICs – include a lack of awareness and knowledge; poor prescription 
practices and a lack of patient adherence to treatment; oversight including over-the-counter sales; 
social and cultural factors; weak regulation and economic incentives; inadequate access to safe 
water, sanitation and hygiene in health care facilities, households, and farms settings; poor 
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prevention of infection and disease; a lack of equitable access to affordable and quality-assured 
antibiotics, diagnostics, and vaccines; weak food safety and feed production; the large and 
growing burden of animal diseases; the increasing livestock production; the insufficient 
investment in veterinary services and animal health; and inadequate sewage/wastewater 
infrastructures all contribute to the emergence and transmission of antibiotic resistance in 
humans, animals, plants, food, and the environment (18–20). 
1.5 HOW DO ANTIBIOTICS ENTER THE ENVIRONMENT? 
Antibiotics can enter the environment through various anthropogenic sources and pathways such 
as municipal, hospital, and pharmaceutical manufacturing effluents, livestock and plant 
production, and fish and seafood farming. Substantial amounts (up to 90%) of antibiotics 
administered to humans and animals are excreted into waste streams, through urine and feces, in 
their biologically active forms or as active metabolites (21). However, sewage treatment 
plants/wastewater treatment plants (STPs/WWTPs) and other waste management systems are 
only partially effective in their removal that are subsequently released in treated effluent (22, 23). 
Antibiotics can be introduced into soil through manure and sludge land application to crops or 
landfill, and irrigation with reclaimed water (24). They may accumulate in vegetables through 
uptake from manure-amended cropland. Other sources may include agriculture runoff from fields 
containing animal manure and aquaculture ponds (25), and the discharge of landfill leachates of 
antibiotic disposal (26). Accordingly, antibiotic residues have been detected in various 
compartments of the environment including effluents from hospitals, municipal and 
pharmaceutical manufacturing, STPs/WWTPs, receiving environmental compartments (e.g., 
river, lake, sea, ground, and drinking water), aquaculture, soil, manure, and plant in several parts 
of the world (27–31). 
1.6 POTENTIAL ENVIRONMENTAL AND HUMAN HEALTH RISKS OF 
ANTIBIOTIC RESIDUES 
Antibiotic residues are considered as contaminants of emerging concern because of their 
continuous introduction into the environment and their potential adverse effects on the 
environment and human health. In particular, antibiotic residues may promote the emergence of 




Figure 1. Environmental and human exposure to antibiotic residues and antibiotic resistance in the environment (34) 
 
1.6.1 Potential environmental risk of antibiotic residues 
Antibiotic residues in the environment create a selection pressure on the environmental bacteria 
and thus generate environmental reservoirs of antibiotic resistant bacteria and antibiotic 
resistance genes. Antibiotic residues may lead to acquired changes in susceptible bacteria, 
allowing the bacteria to survive and further proliferate as antibiotic resistant bacteria that carry 
antibiotic resistant genes. Mobile genetic elements such as plasmids, transposons, and integrons 
would further enhance the promotion and dissemination of genetic recombination of antibiotic 
resistance genes by conjugation, transformation, or transduction collectively referred to as 
horizontal gene transfer (35). The environmental release of antibiotics in effluents and sludge via 
STPs/WWTPs from anthropogenic sources, combined with direct contact between natural 
bacterial communities and discharged antibiotic resistant bacteria and their resistance genes, is a 
driver for the emergence of resistant strains in various aquatic environmental compartments 
including hospital wastewater (36, 37), municipal wastewater (38), industrial effluent (39), 
STPs/WWTPs (40), and the receiving environment (e.g., river, lake, sea, ground, and drinking 
water) (41–43), aquaculture (44, 45), soil, and vegetables (46, 47). In addition, antibiotic residues 
can have ecotoxicity effects on non-target organisms such as fish, daphnia, algae and other 
aquatic organisms (48). 
Bacterial responses to antibiotics depend on their concentrations; diverse biological responses 
occur in bacteria at different concentrations. Antibiotic residues provide a further opportunity for 
the selection and persistence of antibiotic resistant bacteria in the environment, and this might 
occur at much lower levels than previously assumed. Exposures to very low levels of antibiotic 
concentrations below the Minimum Inhibitory Concentrations (MICs, refers to the lowest 
concentration of an antibiotic that inhibits the visible growth of a target bacteria during the 
incubation period) are sufficient for selecting resistant bacteria. Furthermore, each new 
 
 5 
compound added for certain a combination of antibiotics lowered the Minimum Selective 
Concentrations (MSCs, refers to the lowest concentration of an antibiotic that selects for 
resistance) of the others (49, 50). It should be pointed out that these experiments were performed 
in vitro for single bacterial species and there is a need to further investigate how well these MSCs 
values correlate to their proposed effects in the environment, as the MSCs are likely to differ in 
more complex contexts with multiple species under exposure from multiple antibiotics. 
To determine the potential of antibiotic concentrations in promoting the development of 
antibiotic resistant bacteria, thresholds of Predicted No-Effect Concentrations (PNECs) for the 
development of resistance in the environment (51) were assessed. These PNECs were based on 
applying extrapolation techniques to available MICs for clinically relevant bacteria to promote 
the development and selection of antibiotic resistance included in the MIC-database of the 
European Committee for Antimicrobial Susceptibility Testing (EUCAST) (52). The estimation 
of the upper boundary MSCs from the MICs is analogous to the Lowest Observed Effect 
Concentration (LOEC) values used in the ecotoxicity risk assessment of chemicals in the 
environment. 
1.6.2 Potential human health risk of antibiotic residues 
1.6.2.1 Potential human health risk of exposure to antibiotic residues 
The potential human health risk of ingested antibiotic residues through drinking water or food 
consumption is disrupting the intestinal microbiome compositions and function and inducing 
the emergence of an antibiotic resistant intestinal microbiome. Antibiotic exposure is strongly 
associated with alterations in the intestinal microbiome due to the broad-spectrum effect on the 
host bacterial community rather than on the target bacteria. Once an intestinal microbiome 
homeostasis disturbs, it can lead to various diseases such as an increased susceptibility to 
infections such as diarrhoea, compromised immune homeostasis and tolerance such as 
inflammatory and autoimmune diseases and asthma, and deregulated metabolism such as obesity 
and diabetes. The human intestinal microbiome is an important reservoir and transporter of 
antibiotic resistance genes, and these genes may be transferred in the gut from one bacterium to 
another, including to human pathogens. The dissemination of resistant bacteria can also occur 
among individuals and thus further increase the prevalence of antibiotic resistance in a population 
and across continents. The effects of antibiotics may be cumulative in humans. It can therefore 
be expected that the effects of environmental exposure to antibiotic residues on the human 
microbiome may cumulate across generations (53–58, 58–61). Furthermore, given the especial 
prenatal and early-life susceptibility to antibiotics during critical windows of early development, 
unpredicted adverse consequences may result (62–65). Also, human exposure to antibiotic 
residues might pose toxicity effects, such as allergic reactions, thyroid toxicity, fatal aplastic 
anaemia, carcinogenicity, and mutagenicity (66–71). 
The potential risks of antibiotics to human health are mainly assessed by determining the short-
term effects of the treatments involving high oral doses that usually comprise a single type of 
antibiotic targeting specific pathogens. In contrast, exposure to environmental antibiotic residues 
exhibits a different mode of exposure: long-term exposure to a mixture of antibiotics with a high 
proportion of broad-spectrum antibiotics at a low-dose exposure level. When chemicals from the 
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surrounding environment are combined, a combined adverse effect can potentially occur, even if 
each individual component is harmless or present at low levels, and adverse effects are not 
expected. Chronic exposure to mixtures of antibiotics can potentially be associated with increased 
human health risks (72, 73). The main challenges are how to determine the degree to which 
humans are co-exposed to chemicals, what interactions can occur among these chemicals, and 
what specific human health effects are associated with these chemical mixtures. Possible human 
health risks due to the unintended intake of antibiotics through various exposure routes, such as 
inhalation and dermal contact, have not been fully explored (74, 75). The understanding of the 
absorption of antibiotics whose intake is through these exposure routes and the corresponding 
metabolic response of the intestinal microbiome is limited. This lack of understanding is due to 
the technical challenge of analysing the metabolites of the re-ingested antibiotics at the 
environmental level in the highly heterogeneous gastrointestinal system. 
Assessments of human health risk of antibiotic residues were performed to establish the safety 
of antibiotic residues in human food and drinking water. In order to assess the effect of antibiotic 
residues in food and drinking water on the human intestinal microbiome, a harmonised approach 
to determine the threshold dose that might adversely disturb the microbiome and induce the 
emergence of antibiotic resistant intestinal bacteria was established (76). International regulatory 
bodies have developed guideline VICH GL36 (R) for determining the threshold of 
microbiological Accepted Daily Intake (ADI, refers to a level of daily intake of a compound that 
should not result in an adverse human health effect from direct exposure of an individual in a 
population) for antibiotics. This guideline takes into consideration relevant data including MICs 
data against human intestinal bacteria. To date, thresholds of microbiological ADI for antibiotics 
have not yet been determined due to various challenges. These challenges include how to 
quantify resistance and define thresholds’ levels of change in the gastrointestinal tract with the 
complexity of the intestinal microbiome composition? Data of MICs clinical breakpoints are 
unavailable for some antibiotics. It is worth noting that even where this has been done, 
breakpoints have generally only been determined from clinical isolates, i.e. infections, rather than 
including isolates from healthy people. Thus the human health risk of antibiotic residues remain 
poorly understood. 
1.6.2.2 Potential human health risk of antibiotic resistance development 
Antibiotic residues could accelerate the emergence of antibiotic resistant bacteria and antibiotic 
resistance genes in the environment, and the risks associated with the environmental antibiotic 
resistance refer to the transmission of environmental antibiotic resistant bacteria and antibiotic 
resistance genes to humans through various exposure routes such as drinking water, food 
consumption, inhalation, and dermal contact (77–79). Pathogenic and the human commensal 
antibiotic resistant bacteria have the ability to colonise and proliferate in the human body, and 
pathogenic antibiotic resistant bacteria have the ability to cause infectious disease. Most 
commensal antibiotic resistant bacteria are not pathogens, but they could cumulatively reside in 
the human body and may harbour crucial virulence genes and therefore cause a disease, or they 
could transfer the genes conferring crucial virulence to other commensal human microbiomes. A 
potential transfer of antibiotic resistant bacteria and resistance genes between environment, 
animals, and humans, e.g., through horizontal gene transfer, can occur, posing health threats to 
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humans and animals (80–82). This has led to the recognition of the role of the environment in 
the emergence and dissemination of antibiotic resistance from a One Health Perspective (83). 
Microbial risk assessment is used to evaluate the exposure level and the subsequent risk to human 
health from microbiological hazards. In the context of antibiotic resistant bacteria, environmental 
quantitative microbial risk assessment is in its infancy but is needed to address antibiotic resistant 
bacteria. Human health risk assessments dealing with the behaviour of pathogenic and 
commensal antibiotic resistant bacteria in various environmental compartments, the transfer of 
antibiotic resistant bacteria from the environment to humans, the transmission of antibiotic 
resistant bacteria via various environmental routes, and formal dose−response models with 
respect to a pathogenic antibiotic resistant bacteria are sparse. To date, no assessment of 
microbial thresholds for significant antibiotic resistant bacteria development has been conducted. 
The lack of thresholds data has prevented microbial risk assessment analysis to be developed. 
1.7 ECO-PHARMACOVIGILANCE 
The assessment of the environmental and human health impacts of antibiotic residues is crucial 
for developing targeted policies and risk mitigation measures. Therefore, it is essential to 
emphasise the eco-pharmacovigilance system for assessing the potential risk of antibiotic 
residues on the environment. Eco-pharmacovigilance has been proposed as a kind of 
pharmacovigilance for the environment (84, 85). Eco-pharmacovigilance involves activities 
associated with the detection, evaluation, understanding, and prevention of adverse effects of 
pharmaceuticals in the environment. This can be assessed by implementing the environmental 
risk assessment for the existing and new pharmaceuticals. The concerns about the environmental 
health paved the way in developing regulatory guidelines for assessing the risk of 
pharmaceuticals in the environment. However, mechanism exists in regulatory bodies to include 
environmental risk assessment for all new marketing authorisation applications, provided risks 
are identified before approval. Pharmaceuticals that have already been authorised, are not subject 
to a retrospective environmental assessment. Thus, the significance of trace levels of these 
pharmaceuticals in the environment and human health is often poorly understood. Importantly, 
most of the current guidelines do not recognise that the issue of antibiotic resistance development 
may be the most important risk associated with the occurrence of antibiotic residues in the 
environment (86). An addendum emphasising the need to assess the risks posed by antibiotics in 
promoting antibiotic resistance emergence should be included in these guidelines. In the case of 
antibiotics, information on potential environmental impacts must be taken into account in the 
pharmacovigilance system. However, compliance with risk mitigation measures, therefore, has 
only a voluntary character, and their implementation is not systematically verified nor followed 
up on. As such, this asserts the need to implement eco-pharmacovigilance systematically. In 
recognition of the One Health perspective, the impact of pharmaceuticals in the environment on 
One Health might need to be included in the definition of eco-pharmacovigilance (84, 87, 88). In 
doing so, eco-pharmacovigilance would be defined as “the science and activities associated with 
the detection, evaluation, understanding and prevention of adverse effects of pharmaceuticals in 




2 THESIS RATIONALE 
Antibiotic residues are recognised as contaminants of emerging concern due to their 
environmental and human health effects, especially their potential risk in promoting antibiotic 
resistance. Various anthropogenic sources such as the pharmaceutical industry, hospitals, and 
municipal wastewater release antibiotic residues into the environment. However, the 
understanding of the environment as a source and dissemination route for antibiotic residues and 
antibiotic resistance, and the magnitude of the human health risks posed by it, currently has been 
emphasised as a critical research need, as antibiotic resistance can also be co-released into the 
environment with antibiotic residues (33, 89). Antibiotic residues in various environmental 
compartments have been measured in several countries but how exactly they pose a health or 
resistance built up threat, has not been demonstrated. To define the risks to the environment and 
human health and to inform policy, there is a particular need to assess the antibiotic 
concentrations in all types of the environmental compartments at which resistance might develop 
and pose a health threat. These risks are more threatening in LMICs, including those populated 
in the Western Pacific Region (WPR) and the South-East Asia Region (SEAR) of the WHO, 
particularly China and India, which are large densely populated nations and are among the 
world’s largest producers and consumers of antibiotics in human and veterinary medicines (17, 
18, 90). In addition, the knowledge and the relative quantification about the adverse effects of 
antibiotic residues on the human health and non-targeted organisms, such as the chronic toxicity 
and resistance, remain scarce (91). Since multiple numbers of antibiotics are in use concurrently 
in variable quantities, the challenge is to identify which of these antibiotics should be prioritised 
for further assessment and environmental management of antibiotic residues. Therefore, a 
quantitative risk assessment approach to understanding the environmental and human health risks 
of antibiotic residues in an integrated manner, and adequate evaluation prioritisation strategies 










3 AIM AND OBJECTIVES 
3.1 AIM 
The overall aim was to assess the potential environmental and human health risks of exposure to 
antibiotic residues and antibiotic resistance in various environmental compartments of the WPR, 
the SEAR, particularly China and India, and to develop methods for the prioritisation of 
antibiotics to deal with aspects of their resistance and toxicity risks on human health and 
various aquatic environmental compartments. 
3.2 OBJECTIVES 
The specific objectives were: 
 To investigate the occurrence of antibiotic residues in different types of environmental 
samples including water samples in rural eastern China, and to characterise the 
environmental risk for the development of resistance to antibiotic residues in the 
environment as well as the potential human health risk of exposure to antibiotic residues 
via drinking water and vegetables. (Study I) 
 
 To investigate the occurrence of antibiotic residues and antibiotic-resistant Escherichia 
coli (E. coli) in the water and sediment of the Kshipra river in India at seven selected sites 
during different seasons over a 3-year period, and to investigate the association between 
antibiotic residues and antibiotic-resistant E. coli in water and sediment and measured 
water quality parameters of the river. (Study II) 
 
 To investigate the occurrence and concentration of reported antibiotic residues in various 
aquatic environmental compartments of the WPR and SEAR, to assess antibiotic 
exposures in various aquatic environmental compartments for concentrations of 
antibiotics that are likely to select for resistance, and to identify hot spots and subsequent 
hazards of antibiotic residues for antibiotic resistance emergence in the aquatic 
environments of the WPR, the SEAR, China, and India. (Study III) 
 
 To develop an integrated environment–human risk approach for assessing and 
quantifying both the environmental (resistance and ecotoxicity) and human health 
(resistance and toxicity) risks of antibiotics in various proportions of exposures, and 
developing a system for the prioritisation of antibiotics in various aquatic environmental 







4.1 OVERVIEW OF STUDIES 
An overview of the studies included in the thesis is presented in Table 1. 
Table 1. Overview of studies and their methods 
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4.2 STUDY SETTINGS 
4.2.1 The WPR, the SEAR, China, and India 
Study I, Study II, Study III, and Study IV were conducted in the WPR, the SEAR, China, and 
India. The Asia Pacific Region comprises the WPR and the SEAR and include 48 countries and 
areas with 53% of the world’s total population (93, 94). China belonging to the WPR, with 1.43 
billion people in 2019, and India belonging to the SEAR, with 1.37 billion, have long been the 
two most populous countries of the world, comprising 19 and 18 percent, respectively, of the 
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global total in 2019 (95). China and India are among the world’s largest producers and consumers 
of antibiotics in human and veterinary medicines and are also major contributors to global 
pharmaceutical production (17, 18, 90). Antibiotic residues and antibiotic resistance are widely 
detected in the various environmental compartments of the WPR and the SEAR (31, 96–98). 
Antibiotic resistance and exposure patterns of antibiotic residues in the environment in these 
regions are influenced by the following aspects: a) population growth and expanding urban 
centers (99), b) the rapid growth of antibiotic use in livestock production reflects the increase in 
the demand for meat products following the increase in income per capita, c) the shifting of global 
pharmaceutical manufacturing to Asia (100), and d) the inefficient removal of antibiotics by 
STPs and WWTPs. Further, in these regions ~ 80–90% of wastewater is released untreated into 
various water sources (101). 
4.2.2 Study areas 
Study I was conducted in 12 villages in Shandong province in eastern China. The province has 
a population of 96 million in 17 cities and 140 counties, of which around half are rural (Figure 
2). 
 







Study II was conducted within the reaches of the Kshipra river that flows through the city of 
Ujjain in India. The Kshipra River is 195-km long, of which 93 km flows through Ujjain District. 
It originates in the Kokri Bardi Hills (747-m high). After crossing a 70-km pathway, it enters 
Ujjain District (Figure 3). 
 
Figure 3. Geographical location of the study site. The map shows (clockwise) India, Madhya Pradesh, the sampling 
points on the Kshipra river, and Ujjain district. 
 
Study III was conducted in the WPR and SEAR, the WPR, including American Samoa (USA), 
Australia, Brunei Darussalam, Cambodia, China, Cook Islands, Fiji, French Polynesia (France), 
Guam (USA), Hong Kong SAR (China), Japan, Kiribati, Lao People's Democratic Republic, 
Macao SAR (China), Malaysia, Marshall Islands, Federated States of Micronesia, Mongolia, 
Nauru, New Caledonia (France), New Zealand Niue, Northern Mariana Islands, Commonwealth 
of the (USA), Palau, Papua New Guinea, Philippines, Pitcairn Islands (UK), Republic of Korea 
(South Korea), Samoa, Singapore, Solomon Islands, Tokelau, Tonga, Tuvalu, Taiwan, Vanuatu, 
Viet Nam, Wallis and Futuna (France), and the SEAR, including Bangladesh, Bhutan, 
Democratic People's Republic of Korea, India, Indonesia, Maldives, Myanmar, Nepal, Sri Lanka, 
Thailand, and Timor-Leste. 
Study IV was methodology development, to demonstrate the utility of the proposed approach, it 
was applied to the situation of China, China being just an example. 
4.3 STUDY DESIGN, DATA MANAGEMENT, AND ANALYSES 
Study I 
Quantitative methods for determining antibiotic concentrations in various environmental 
compartments of Shandong province in China were used, and risk assessment methods to 
characterise its environmental and health risks were performed. 
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Environmental samples (n = 214) were collected from the 12 villages, over six consecutive days 
in July 2015. The samples consisted of different types of water (well, surface, tap, and 
wastewater), sediments, pig manure, soil, and parts of the vegetables that are edible for humans. 
In each village, at least two households with animal breeding were included in the study. In each 
household, one sample each was taken from one human and one animal drinking water container. 
If for humans and animals different drinking water sources were used, e.g., well water for animals 
and tap water for humans, then both would be sampled. If humans and animals used the same 
drinking water, only one drinking water sample was taken. In addition, wastewater, manure, and 
outlet sediments were also sampled from the same household. If the village was near the river, 
water and sediment from the river were sampled. For vegetables, different types of edible parts 
such as cucumbers, tomatoes, lettuces, and kidney beans etc. were sampled. 
To test the level of antibiotic residues in the environmental samples, target antibiotics were 
selected based on their usage in humans and animals in China, particularly in the target area, as 
well as their behaviours in the environment. Norfloxacin, levofloxacin, ciprofloxacin, 
enrofloxacin, doxycycline, sulfapyridine, sulfamethoxazole, metronidazole, florfenicol, and 
chloramphenicol were analysed by using the high performance liquid chromatography-tandem 
mass spectrometry (HPLC-MS/MS) technique. 
The concentrations of antibiotic residues are reported as median, mean, and range for each target 
antibiotic for each type of sample. 
The environmental risk for the development of resistance to antibiotics was estimated by means 
of risk quotient (RQ) values. PNECS (ng/L) for the development of resistance (51) were 
employed for these calculations. Based on the MICs for 111 antibiotics from the database of the 
EUCAST (52), these PNECS were assessed with an assessment factor of 10, corresponding to 
the median MICs / MSCs ratio for clinically relevant bacteria to promote the development of 
antibiotic resistance.  
The RQ values are expressed as the ratio of the Measured Environmental Concentrations (MECs) 
to the PNECs for development of resistance, for any particular antibiotic compound as shown in 
Eq. 1. 
𝑅𝑄 = 𝑀𝐸𝐶𝑠 𝑃𝑁𝐸𝐶𝑠⁄                                                                                                                        (1)  
The risk was classified into three levels, i.e. low risk with the RQ values ranging between 0.01 
and 0.1, moderate risk with the RQ values ranging between 0.1 and 1, and high risk with the RQ 
values > 1 (102). 
To assess the potential risk to human health through exposure to antibiotic residues in drinking 
water, the approach of ADI was used in this study to assess the potential risk to human health 
through the exposure to antibiotic residues in drinking water. It was combined with the standard 
assumptions to derive Predicted No Effect Concentrations for drinking water (PNECDW). 
PNECDW was estimated for both adults and children using a general exposure equation which 
was consistent with those used by the U.S. Environmental Protection Agency (U.S. EPA) for 
developing concentration limits to protect against threshold-type effects, such as the Ambient 
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Water Quality Criteria (AWQC), for the protection of human health, or maximum allowed 
contaminant levels. PNECDW was calculated using Eq. 2. 
𝑃𝑁𝐸𝐶𝐷𝑊 = (1000 ∗ 𝐴𝐷𝐼 ∗ 𝐵𝑊 ∗ 𝐴𝑇) (𝐼𝑛𝑔𝑅𝐷𝑊 ∗ 𝐸𝐹 ∗ 𝐸𝐷)⁄                                                     (2) 
PNECDW represents what the predicted no effect concentrations for drinking water is (ng/L); 
1000 is a conversion factor (ng/μg); ADI is the accepted daily intake (μg/kg/day); BW is the child 
or adult body weight (kg/person); AT is the average time of exposure (days); IngRDW is the child 
or adult drinking water ingestion rate (L/person/day); EF is the exposure frequency (days/year); 
ED is the exposure duration (years). The equation was applied using human exposure parameters 
recommended by the U.S. EPA guidance for deriving AWQC and WHO Guidelines for Drinking 
water Quality (103,104). 
I calculated the ratios of MECs/PNECDW for each compound to estimate the potential health risk, 
a ratio of MECs/PNECDW of > 1 was identified as a potential risk to human health. 
I calculated the potential risk by vegetable consumption according to the ADI in μg/kg/day of an 
antibiotic present in the vegetables. ADI is established to provide a guide for the maximum 
quantity of a single chemical or drug that can be taken daily in food without an appreciable health 
risk to the consumers (105). 
The Estimated Daily Intake (EDI) values were calculated for adult and child, using Eq. 3. 
𝐸𝐷𝐼 = (𝐶𝑓𝑜𝑜𝑑 ∗ 𝐼𝑅𝑣𝑒𝑔 ∗ 𝛽𝑔 𝑐𝑢𝑝⁄ ∗ 𝛽𝑤𝑤 𝑑𝑤⁄ ) 𝐵𝑊⁄                                                                        (3)  
Cfood represents the mean concentration of an antibiotic in vegetables (ng/g dry weight (dw)). 
IRveg represents 3.45 cup equivalents of vegetables per day for an adult in China (276 g/d), and 
2.86 cup equivalents of vegetables per day for a child in China (228.8 g/d) (i.e. 1 cup = 80 g of 
raw vegetable) (106, 107). βg/cup represents the mass of a cup of fresh tissue diced to ≤ 0.5 cm
3 
(i.e. g/cup equivalent), which was determined in the laboratory. βww/dw represents the mean wet-
to-dry conversion factor used by the U.S. EPA for plant tissue in the development of soil 
screening values (i.e. 0.085) (108). BW is the child or adult body weight (kg/person). 
I calculated the ratios of EDI/ADI for each antibiotic to estimate the potential health risk, a ratio 
of EDI/ADI of > 0.1 was identified as a potential risk to human health. 
Study II 
Quantitative methods to investigate the antibiotic residues’ levels and water quality in the river 
water and sediment samples from the Kshipra river during different seasons, seven sampling 
sites over a 3-year period were used, and microbiological and molecular methods to test 
antibiotic resistant E. coli and antibiotic resistance genes were applied. 
Water and sediment samples from the Kshipra river were collected from seven selected sites, 
and water samples were collected in duplicate. Sampling was conducted once during each of 
the four seasons for three consecutive years: 2014, 2015, and 2016. The criteria for the 
sampling sites included both point and non-point sources of pollution, and the locations were 
chosen at places which have industries and agriculture activities, and at the confluence of the 
 
 15 
Khan and Kshipra rivers. The Khan river brings pollutants from pharmaceutical industries 
nearby. Further, there were mass-bathing spots or spiritually important places where the 
pollution load was expected to be high due to the bathing of people. 
The methods are described in brief here; a detailed description of the methods is available in the 
published protocol (109). Water and sediment water quality parameters were measured. Further, 
river water and sediment samples were analysed for the presence of antibiotics: ceftriaxone, 
ofloxacin, norfloxacin, ciprofloxacin, sulfamethoxazole, metronidazole, and total residual 
antibiotics as β-lactam. These antibiotics were selected based on antibiotic residues previously 
found in the same geographical area (110), environmental stability, and known and suspected 
environmental impacts of the antibiotic and the degree of antibiotic metabolism (111).  Antibiotic 
residues were detected by using the LC-MS/MS technique. 
Susceptibility tests for eight different classes of antibiotics inclusive of ampicillin, cefotaxime, 
ceftazidime, cefepime, nalidixic acid, ciprofloxacin, nitrofurantoin, gentamicin, amikacin, 
tetracycline, tigecycline, imipenem, meropenem, co-trimoxazole, and sulfamethiazole were 
conducted using the Kirby Bauer disc-diffusion method (112). Clinical and Laboratory Standard 
Institute (CLSI) guidelines were used to measure and interpret the zone diameter of bacterial 
growth inhibition (113). Antibiotic resistance genes such as ESBL-coding, plasmid-mediated 
quinolone resistance, carabapenemase resistance, and sulfonamide resistance genes were 
analysed from the river water and sediment samples by polymerase chain reaction (PCR). 
An analysis of variance (ANOVA) was conducted to determine seasonal variation in antibiotic 
residues and resistance among the seven sites over a 3-year period. A post-hoc analysis was 
applied to test the difference in antibiotic residues and resistance between seasons within each 
year. The Tukey correction was used to adjust p-values for multiple pairwise comparison. 
Correlations between antibiotics and water quality parameters were analysed with Pearson’s rank 
correlation test. 
Study III 
I conducted a systematic review of the literature published between 2006 and 2019 to investigate 
the occurrence and concentrations of the reported antibiotic residues in various aquatic 
environmental compartments of the WPR and SEAR. I also used risk assessment methods 
including Probabilistic Environmental Hazard Assessments (PEHA) to assess antibiotic 
exposures in various aquatic environmental compartments for concentrations of antibiotics that 
are likely to select for resistance. 
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
guidelines were followed (114). 
Eligibility criteria were specified a priori as original research articles of any quantitative design 
related to the subject matter. Studies were included if they a) were original, b) reported antibiotics 
or antibacterials employed for systemic use in humans or animals, c) reported any type, group, 
or class of antibiotic, d) collected any type of water samples from the environment, such as: river 
water, lake water, drinking water, ground water, sea water, or other water compartments (surface 
water, canal, pond, stream, surrounding aquaculture, reservoir drainage, estuary, nearshore, and 
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offshore), wastewater (municipal, hospital, and pharmaceutical manufacturing), and 
STPs’/WWTPs’ influents and effluents, e) measured antibiotic residue concentrations in one or 
several of the aquatic environments, f) for studies conducted in the WPR and SEAR, g) published 
from 2006 to 2019, and h) there were no language restrictions and grey literature (conference 
abstracts, dissertations) was searched. Studies were not included if they only reported antibiotic 
residues in non-water samples (soil, sediment, manure, and vegetables). 
I conducted the literature search using various scientific literature databases such as Medline 
(OVID), Web of Science, Embase, Global Health (OVID), GreenFile, Dissertations and Theses 
(ProQuest), and WHO IRIS. I performed the searches in October 2018 and updated it in 
December 2019. The first screening stage (relevance screening) consisted of an evaluation of 
titles and abstracts of all records retrieved, to retain only those relevant to the review question. 
The full texts of eligible papers were assessed according to the pre-defined inclusion and 
exclusion criteria in the second screening stage. 
Considering the threats to internal validity, I assessed each included study for risk of bias in three 
domains: selection bias, information bias, and confounding. For each domain, each study was 
evaluated as having either a low, high, or unclear risk of bias. For each study, I assessed overall 
risk of bias by combining risk of bias from each domain. In this study, I adapted the format for 
assessing risk of bias and critical appraisal criteria to assess the studies from the Cochrane 
Collaboration Risk of Bias Tool and other tools from previous studies (115, 116). They were 
adjusted to our research question of environmental interest to create our own tool. Studies were 
included irrespective of how it was judged in terms of quality and risk of bias. 
I extracted data on antibiotic concentrations, for reported measured antibiotic residues from the 
papers and clustered them by each aquatic environmental compartmental media/system to 
include the following items: a) author, b) year, c) journal, d) location, e) country, f) compartment, 
g) chemical, h) concentration ng/L (min, max, mean, and median), i) removal efficiency for 
STPs/WWTPs, j) detection limit, k) instrumentation, l) sample size/sampling notes, m) notes, 
and n) full citation. 
After the data were extracted and compiled from the primary literature, they were utilised to 
perform PEHA. In which the likelihood of the environmental occurrence of each antibiotic 
exceeding the thresholds for the development of antibiotic resistance, in various proportions of 
exposure, in various aquatic environmental compartments of the WPR, the SEAR, China, and 
India were estimated. The PEHA approach is currently being assessed for incorporation into 
assessment procedures in a number of regulatory jurisdictions and literatures. PEHA is used to 
estimate the exposures of populations and communities to potentially hazardous materials and 
their responses to these exposures, and to predict the magnitude and probability of the effects, 
where the probability is the characterisation, quantitatively, of the uncertain variables (117–120). 
I formulated PEHA models using Environmental Exposure Distributions (EEDs) of the 
maximum Measured Environmental Concentrations (mMECs) of antibiotics for each water 
compartment. As maximum, mean, and median values were not consistently reported in the 
studies/literature and to conservatively maximise the estimates of exposure, mMECs of 
antibiotics were used for hazard assessments of aquatic environmental compartments. 
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Reported mMECs of antibiotic were ranked in ascending order, and the percent rank assigned 
using a Weibull formula: 
𝑗 = (𝑖 ∗ 100) (𝑛 + 1)⁄  
Where, j is the percent rank, i is the rank assigned to the mMECs of an antibiotic, n is the number 
of data points. A linear regression was then fitted to the percent rank versus mMECs plot 
(probability transformed and log normal scales, respectively; SigmaPlot 12.0). For each 
regression related to each aquatic environmental compartment, the slope, intercept, and r2 were 
determined. The resulting slope and intercept from the linear regression were used to estimate 
the probabilities of observing mMECs at given concentrations with the NORMDIST function in 
Microsoft Excel, using the equation: 
𝑐𝑒𝑛𝑡𝑖𝑙𝑒 𝑣𝑎𝑙𝑢𝑒 = 𝑁𝑂𝑅𝑀𝐷𝐼𝑆𝑇 ((𝑚 ∗ 𝑙𝑜𝑔10 (𝑥)) + 𝑏) 
Where NORMSDIST returns the standard normal cumulative distribution function, x is the 
threshold value, m is the slope of the regression, and b is the intercept. 
I calculated the predicted threshold concentrations of the corresponding different centiles (1, 5, 
25, 50, 75, 95, and 99) for the measured environmental concentrations distribution of the 
maximum reported antibiotic residues in various aquatic environments, and I determined the 
percent exceedances of antibiotic thresholds for the development of resistance. The thresholds of 
PNECs (ng/L) for the development of resistance (51) were employed for these calculations. 
PEHA does not generate a single point estimate, but rather produces a likelihood and range that 
a particular exposure and effect will occur. Accordingly, this type of assessment allows the risk 
assessors or managers (e.g., decision making and/or regulatory agency, policy maker, or 
industries) to conduct the assessment independent of most value judgments, to predict the 
likelihood that a certain level of protection would be attained. For instance, the assessor may 
require that the environmental concentration associated with the level of protection be 
exceeded only 5% of the time (alternatively, 95% of all exposures (water concentrations) would 
be expected to be equal to or less than the required environmental concentration). Using these 
centile levels depending on the resources available to the risk managers and the capacity and 
applicability, they then take appropriate actions. Then they do not work in a void but have some 
understanding of what resistance reduction their actions are likely to have. PEHA also allows 
the analysis of variability (refers to the heterogeneity and diversity) and uncertainty (refers to 
imperfect knowledge or a lack of a precise knowledge) to be incorporated into exposure and/or 
hazard assessments. 
Study IV  
I developed an integrated environment–human risk approach for the quantitative environmental 
and human health risk assessment of antibiotics and a prioritisation system thereof.  
Conceptually, the specificities of the approach I propose are: a) a risk-based approach suitable 
for the initial assessment and prioritisation of antibiotics that are of interest for management 
purposes and further research; b) the approach combines data on exposure, data on toxicity, 
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data on resistance, and the chemical structures of antibiotics with PEHA and the Threshold of 
Toxicological Concern (TTC) approach; c) the approach enables the researcher to assess and 
quantify the environmental risks (resistance and ecotoxicity) and the human health risks 
(resistance and toxicity) regarding the chronic exposure of maximum concentrations of 
antibiotic residues in various aquatic environmental compartments in various proportions of 
exposure and d) the approach enables the prioritisation of antibiotics in various aquatic 
environmental compartments. Based on the data availability, this approach could be adjusted 
for any environmental compartments. Previous studies that compared a set of previously 
proposed ranking methods / prioritisation schemes for environmental risk assessment reported 
that risk-based approaches are preferred over hazard-based methods since environmental risk 
reflects both exposure and impact or inherent hazards of the pharmaceuticals (24). For risk-
based decisions, when the risk and data gap of antibiotics are identified, follow-up work is 
required to identify targeted policies in accordance with the level of risk, to minimise it or to 
refine the environmental risk assessment. 
The following sections present descriptions of the development of the data collection and 
assessment schemes and the antibiotic prioritisation system.  
Data collection and assessment 
I conducted a systematic review of the literature published between 2006 and 2019 to investigate 
antibiotic residues in all aquatic environmental compartments of China. After data on 
environmental concentrations of antibiotic residues were extracted and compiled from primary 
literature, they were utilised to assess the environmental risk and human health risk of antibiotics 
by performing PEHA (our unpublished data from Study III, to be published separately). 
Environmental risk 
I assessed environmental risk for resistance risk and ecotoxicity risk of antibiotic residues in 
surface water (river water, lake water, sea water, other water compartments, waste water, 
WWTPs’ influents and WWTPs’ effluents) and ground water in China. 
Resistance risk on environment 
Resistance risk was estimated by combining actual data on the exposure of the mMECs of 
antibiotic residues for each water compartment including surface water (river water, lake water, 
sea water, other water compartments, waste water, WWTPs’ influents and WWTPs’ effluents) 
and ground water in China, the thresholds of PNECS for the development of resistance, and 
PEHA. 
Ecotoxicity risk 
The likelihood of the environmental occurrence of each antibiotic exceeding the threshold for 
ecotoxicity risk, in various proportions of exposure, in surface water (river water, lake water, sea 
water, other water compartments, waste water, WWTPs’ influents and WWTPs’ effluents) and 
ground water in China were estimated by combining actual data on the exposure of the mMECs 
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of antibiotic residues for each aquatic compartment, the thresholds of the PNECE which represent 
the ecotoxicity, and PEHA.  
The Environmental Risk Assessment aims to establish the safe concentrations for the protection 
of ecosystem structure and function, wildlife populations, and includes the calculation of PNECE 
for aquatic organisms, namely PNECEgroundwater (PNECEgw), PNECEsurfacewater (PNECEsw) and 
PNECEmicroorganism (86). The PNECEgw is based on a chronic test with Daphnia magna (121) and 
PNECEsw is calculated from the toxicity for three aquatic species – green algae, invertebrate and 
fish. PNECEgw and PNECEsw were calculated by taking the lowest No Observed Effect 
Concentration (NOEC, the test concentration at which there is no statistically significant effect 
in the response being tested, such as on growth rate or reproduction), or 50% Effective 
Concentration (EC50, refers to the concentration of a toxic compound inducing the response to 
50% of the maximal possible effect from an organism) if NOEC was not available for aquatic 
species, and applying an assessment factor (AF) according to the European technical guidance 
(102). The AF was applied to account for inter-species and intra-species variations; the 
extrapolation of short-term toxicity towards long-term toxicity; and the laboratory data to field 
impact extrapolation, as described in the regulatory guidance (86). The PNECEgw and PNECEsw 
were calculated using Eq.  (1). In chronic tests (long-term), lethal and sub-lethal effects are 
measured. The latter includes evaluations of growth reduction, reproductive impairment, lack of 
mobility and inhibition of some regulatory functions such as development, fertility, changes in 
behaviour and maintenance of homeostasis (122). The NOEC or EC50 of antibiotics was retrieved 
from a systematic review, which reported the lowest 'reliable' NOEC and EC50 of taxa commonly 
used in environmental risk assessment for antibiotics (123). 
𝑃𝑁𝐸𝐶 = 𝑁𝑂𝐸𝐶 𝑜𝑟 𝐸𝐶50 𝐴𝐹⁄                                                                                                        (1) 
The bioaccumulation of an antibiotic is represented using its octanol–water partition coefficient 
(LogKow) value. This indicator was used to represent the chemical's bioaccumulation attribute 
as it has been correlated with the bioconcentration factor for different ionic and non-ionic 
compounds as well. A LogKow value of more than 4.5 indicates a potential for the 
bioaccumulation of a chemical (86). Information on the bioaccumulation of antibiotics was 
retrieved from a review study of Physicochemical properties of antibiotics (124) and the 
PubChemDatabase, 2019.  
Human health risk 
I assessed the human health risk  regarding resistance risk and toxicity risk of antibiotic residues 
in both drinking water and ground water (in the literature, antibiotic residues’ information was 
available separately for drinking water and ground water).  
Resistance risk on human health  
The likelihood of the environmental occurrence of each antibiotic exceeding the threshold for the 
development of antibiotic resistance was assessed by combining actual data on the exposure of 
the mMECs of antibiotic residues in drinking water and ground water in China, thresholds of 
PNECS for the development of resistance, and PEHA. 
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Due to the lack of human health thresholds for the development of resistance data, the assessment 
of the human health risk of antibiotic residues via drinking water and ground water was based on 
the threshold of PNECS for the development of resistance. The assumption was made that if the 
likelihood of exceedances of antibiotic PNECS for the development of resistance are observed 
for antibiotic residues in drinking water and ground water, these antibiotics have the potential 
risk for the development of antibiotic resistance in human intestinal microbiome.  
Toxicity risk on human health 
The likelihood of the environmental occurrence of each antibiotic exceeding the threshold for 
toxicity risk was assessed by combining actual data on the exposure of the mMECs of antibiotic 
residues in drinking water and ground water in China, Threshold of Toxicological Concern 
(TTC) approach, and PEHA. 
The TTC approach is a screening tool that has been developed in order to assess substances of 
unknown toxicity present at low levels in the food and drinking water, and to prioritise chemicals. 
TTC values are intended to represent exposure thresholds below which there is no appreciable 
risk to human health over a lifetime of daily exposure for chemicals of that class, based upon 
structural characteristics of the chemical in question and existing toxicity data for other 
substances in an identified database. A large database of reference substances was compiled from 
which a distribution of NOELs could be derived. Three classes were identified based on the 
toxicity in ascending order: Cramer class I, II, and III (125). TTC utilises different systemic 
endpoints, such as developmental and reproductive toxicity, immunotoxicity and neurotoxicity. 
A Cramer classification of each of the antibiotics was performed using ToxTree version software 
(https://apps.ideaconsult.net/data/ui/toxtree). The TTC approach relies on conservative daily 
exposure thresholds (NOEL) for each Cramer class, derived from a database of sub-chronic, 
chronic and reproductive / developmental oral toxicity data on more than 600 chemicals (126, 
127). Each TTC value represents the 5th percentile NOEL of all compounds in the dataset for 
that particular class (i.e., 95% of the compounds in the class were less toxic). Short-term testing 
is generally not applicable for human pharmaceuticals since continuous exposure of the aquatic 
environment via drinking water is assumed. TTC values were obtained by dividing the respective 
TTC values for the appropriate Cramer class (1800, 540 and 90 ug/day for classes I, II and III, 
respectively) by 60 (adult body weight in kilograms), to express the values per unit of body 
weight. Accordingly, Cramer class I chemicals have human exposure threshold values of 30 
ug/kg body weight per day; class II, 9 ug/kg body weight per day; and class III, 1.5 ug/kg body 
weight per day. A TTC value of 1.5 ug/kg body weight per day would provide an adequate margin 
of safety for both non-cancer and cancer endpoints (128).  
The TTC values are total oral exposures per person per day. To derive drinking water target 
values, these therefore need to be translated to drinking water concentrations. According to the 
WHO guidelines for drinking water quality 2011, there is variation in both the body weight of 
consumers and volume of daily water consumed. Therefore, assumptions were applied in order 
to determine a guideline value. The default assumption for body weight is 60 kg, whereas the 
default assumption for adult consumption is 2 litres of water per day. In order to account for the 
variations in exposure from different sources of default values, generally 10 % is used. Wherever 
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possible, country- or site-specific information should be used in assessments of this type. If no 
specific data are available, an approximate risk estimate can be based on default values (129).  
The standard WHO drinking water consumption rate of 2 L/day for adults (60 kg) is used. Using 
the TTC value of 1.5 ug/kg body weight per day, the following target value can be derived:  
(1.5 ug/kg body weight per day ∗ 10%) / 2 L ≈ 0.1 ug/L ≈ 100 ng/L.  
According to EMA 2015 (130), as part of the environmental risk assessment, the concentrations 
in groundwater of antibiotic residues need to be compared against the value of 100 ng/L. 
Concentrations above 100 ng/L have been considered unacceptable for all substances, regardless 
of their intrinsic hazardous properties. In this situation, applicants could refine the concentrations 
of groundwater and drinking water with additional data (e.g., modelling, more studies e.g., on 
degradation in manure, mitigation measures). For concentrations below 100 ng/L, no risk was 
anticipated and no further regulatory action was required.  
Antibiotic prioritisation system 
The proposed antibiotic prioritisation system consists of criteria, attributes, sub-attributes and 
sub-sub-attributes.  
Criteria, attributes, sub-attributes and sub-sub-attributes 
The ranking of antibiotics in this study was based on the overall scores of two criteria: a) 
environmental risk and b) human health risk of antibiotic residues.   
The first criterion “environmental risk” was represented using two attributes: a) resistance risk: 
was represented as the likelihood of the environmental occurrence of each antibiotic exceeding 
the thresholds for the development of antibiotic resistance, which was represented using eight 
sub-attributes (river water, lake water, ground water, sea water, other water compartments, waste 
water, WWTPs’ influents and effluents), and b) ecotoxicity risk: was represented using two sub-
attributes: b1) ecotoxicity, which was represented as the likelihood of the environmental 
occurrence of each antibiotic exceeding the thresholds for ecotoxicity, which was represented 
using eight sub-sub-attributes (river water, lake water, ground water, sea water, other water 
compartments, waste water, WWTPs’ influent and effluent), and b2) bioaccumulation, which 
was represented using its octanol–water partition coefficient (LogKow) values.  
The second criterion, “human health risk”, was represented using two attributes: a) resistance 
risk: was represented as the likelihood of the environmental occurrence of each antibiotic 
exceeding the thresholds for the development of antibiotic resistance, and was represented using 
two sub-attributes (ground water and drinking water), and b) toxicity risk: was represented as the 
likelihood of the environmental occurrence of each antibiotic exceeding the thresholds for human 
toxicity, which was represented using two sub-attributes (ground water and drinking water). 
Utility functions 
All of the criteria, attributes, sub-attributes and sub-sub-attributes have numerical values. 
Expressions of utility functions were chosen to reflect the fact that an antibiotic with a high 
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potential of resistance risk, a high potential of toxicity or a high logKnow (value indicates a 
potential for bioaccumulation) should have a high overall rank score and prioritisation in water.  
However, other variations of utility functions are possible. For example, the overall ecotoxicity 
risk attribute can be expressed separately using individual ecotoxicity risk attributes for aquatic 
species. Further, in the absence of any data, the utility function of an attribute was assigned 0. 
Multiple criteria, attributes, sub-attributes and sub-sub-attributes have different importances in 
influencing the overall ranking of antibiotics in water and were expressed as importance weights. 
For each category (i.e., criteria, attributes, sub-attributes or sub-sub-attributes), the total sum of 
importance weights remains 1. The calculated importance weights of the components of a 
representative utility function are presented in Table 2. An illustration of the steps for calculating 
rank scores and data gaps is presented in Appendix 1 using ciprofloxacin as a representative 
antibiotic. 
 
Table 2. Calculated importance weights of components of a representative utility function of criterion, attribute, 
sub-attribute, and sub-sub-attribute  
 
Category Component  Importance weights * 
Criterion Environmental risk  1/2 
Attribute Resistance risk 1/2 
Sub-attribute River water 1/8 
Lake water 1/8 
Ground water 1/8 
Sea water 1/8 
Other water compartments 1/8 
Wastewater 1/8 
WWTP influent 1/8 
WWTP effluent 1/8 
Attribute Ecotoxicity risk 1/2 
Sub-attribute Ecotoxicity 1/2 





Lake water 1/8 
Ground water 1/8 
Sea water 1/8 
Other water compartments 1/8 
Wastewater 1/8 
WWTP influent 1/8 
WWTP effluent 1/8 
Sub-attribute Bioaccumulation 1/2 
Criterion Human health risk 1/2 
Attribute Resistance risk 1/2 
Sub-attribute Drinking water 1/2 
Ground water 1/2 
Attribute Toxicity risk 1/2 
Sub-attribute Drinking water 1/2 
Ground water 1/2 
*In this study, all criteria are assumed to be equally important; all attributes for a given criterion are assumed to be 
equally important; all sub-attributes for the given attribute are assumed to be equally important; all sub-sub-
attributes for the given sub-attributes are assumed to be equally important. 
 
Overall rank score (Roverall) 
I calculated the overall score of a given ith antibiotic using Eq. (2), where Ri,overall represents the 
overall rank scores of the antibiotic, Rj,i represents the score of the corresponding criterion, Wj,i 
represents the importance weight of the jth criterion and N represents the total number of criteria. 
Similarly, as the two criteria were also considered equally important to avoid any judgment bias, 
the value of Wj,i was set as 1/2. 
   𝑅𝑖,𝑜𝑣𝑒𝑟𝑎𝑙𝑙 = ∑ 𝑅𝑗,𝑖
𝑁
𝑗=1 ∗ 𝑊𝑗,𝑖                                                                                                       (2) 
An expression for calculating an overall rank score of a given ith antibiotic can be written as 
Ri,overall = Re,i ∗ We,i + Rh,i ∗ Wh,i where We,i and Wh,i  represent the importance weights of the 
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environmental risk (e) and the human health risk (h) criteria, respectively (each assumed to be 
equal to ½ in this study). Here, Re,i and Rh,i  represent the rank scores of the environmental risk 
and the human health risk criteria, respectively. 
The rank scores of multiple criteria (Rj,i) were calculated using Eq. (3), where Rk,j,i, represents an 
attribute-based rank score, Wk,j,i  is the importance weight of each attribute for a kth attribute of 
a jth criterion, and N represents the total number of attributes. If the criterion has two attributes, 
both of them are considered equally important. Therefore, the importance weight Wk,j,i was 
assigned ½ . 
  𝑅𝑗,𝑖 = ∑ 𝑅𝑘,𝑗,𝑖
𝑁
𝐾=1 ∗ 𝑊𝑘,𝑗,𝑖                                                                                                           (3) 
An expression for calculating a rank score for the environmental risk criterion (Re,i) (attributes: 
resistance risk (e1) and ecotoxicity risk (e2)); can be written as Re,i = Re1,e,i ∗ We1,e,i  + Re2,e,i ∗ 
We2,e,i where We1,e,i and We2,e,i represent the importance weights of the resistance risk and the 
ecotoxicity risk attributes, respectively. Here, Re1,e,i and Re2,e,i represent rank scores of the 
resistance risk and the ecotoxicity risk attributes, respectively. A similar expression was 
developed for calculating the rank scores of the attributes, sub-attributes and sub-sub-attributes.  
An expression for calculating a rank score for the human health criterion (Rh,i) (attributes: 
resistance risk (h1) and toxicity risk (h2)); can be written as Rh,i = Rh1,h,i ∗ Wh1,h,i + Rh2,h,i ∗  Wh2,h,i 
where Wh1,h,i and Wh2,h,i  represent the importance weights of the resistance risk and the toxicity 
risk attributes, respectively (assumed to be equal to ½ for each attribute). Here, Rh1,h,i and Rh2,h,i 
represent the rank scores of the resistance risk and the toxicity risk attributes, respectively. 
Similar expressions were developed for calculating the rank scores of the attributes and sub-
attributes.  
Database uncertainty 
A database uncertainty of an antibiotic is represented by calculating an overall data gap rank 
score. For calculating this score, values of utility functions are assigned ½ for attributes, sub-
attributes and sub-sub-attributes with missing data for a given antibiotic and assigned 0 for 
attributes, sub-attributes and sub-sub-attributes with available antibiotic data. In these 
calculations, the values of the importance weights of the criteria, attributes, sub-attributes and 
sub-sub-attributes are kept constant, obtaining values from Table 2. The overall data gap was 
quantitatively calculated using Eq. (4), where Rj,i,datagap represent data gap scores of multiple 
criteria. A data gap score of a criterion is calculated using Eq. (5) and depends on Wk,j,i  and the 
data gap scores of multiple attributes (Rk,j,i,datagap). A similar expression was developed for 
calculating the data gap scores of the attributes, sub-attributes and sub-sub-attributes. 
   𝑅i,datagap = ∑ 𝑅j,i,datagap
𝑁
𝑗=1 ∗ 𝑊𝑗,𝑖                                                                                               (4) 
    𝑅j,i,datagap = ∑ 𝑅k,j,i,datagap
𝑁
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5.1 Antibiotic residues were detected in various environmental compartments of rural    
Shandong province, China. The concentration levels of enrofloxacin, levofloxacin, 
and ciprofloxacin in wastewater were estimated to pose environmental risks for the 
development and selection of antibiotic resistance in bacteria. The concentration of 
antibiotic residues in drinking water and vegetables were estimated to pose no 
appreciable direct risk to human health through consumption (Study I) 
Water samples and non-water samples taken from villages in Shandong province in eastern China 
were found to contain metronidazole, sulfapyridine, norfloxacin, levofloxacin, ciprofloxacin, 
enrofloxacin, doxycycline, sulfamethoxazole, florfenicol, and chloramphenicol. In water 
samples, the mean concentrations detected in river water varied from 0.101 ng/L (metronidazole) 
to 4.359 ng/L (norfloxacin). In wastewater, the range was from 0.0309 ng/L (chloramphenicol) 
to 646.715 ng/L (levofloxacin). The highest concentration in drinking water was for 
ciprofloxacin (6.205 ng/L). For non-water samples, the highest mean concentrations in river 
sediment, outlet sediment, pig manure, soil, and vegetables were found for enrofloxacin (2.205 
μg/kg), ciprofloxacin (80.749 μg/kg), norfloxacin (32.782 μg/kg), ciprofloxacin (2.805 μg/kg), 
and ciprofloxacin (44.584 μg/kg), respectively. 
The RQ values for the estimated environmental risk of antibiotic resistance selection were > 1 
for enrofloxacin (1.821) and levofloxacin (2.587). The RQ value for ciprofloxacin was 0.127, 
and all other RQ values were < 0.1 (Table 3). MECs/PNECDW ratios were < 1 from exposure to 
antibiotics through drinking water for adults and children. EDI/ADI ratios were < 0.1 from 






























Sulfapyridine 10 0.0000135 0.0000569 0.0000052 
Sulfamethoxazole  16 0.0000813 0.000087 0.00013 
Ciprofloxacin  0.064 0.0135 0.127 0.096 
Enrofloxacin 0.064 0.043 1.821 0.0067 
Levofloxacin 0.25 0.00213 2.587 - 
Norfloxacin 0.5 0.0087 0.0035 0.00048 
Chloramphenicol  8 - 0.0000037 - 
Florfenicol 2 0.00046 0.0020 0.00089 
Doxycycline  2 0.000163 0.0065 0.000015 
Metronidazole  0.125 0.00081 0.00139 - 
Abbreviations: PNECs: predicted no effect concentrations for the development of antibiotic resistance, RQ: risk 
quotient. 
 
5.2 Antibiotic residues and resistant E. coli were present in the water and sediment of 
the Kshipra river in India and showed significant seasonal and spatial variations 
over a 3-year period, and had varying associations with measured water quality 
parameters (Study II) 
Antibiotics including norfloxacin, ofloxacin, metronidazole, and sulfamethoxazole were detected 
in the water of the Kshipra river in various seasons from the seven sampling sites over a 3-year 
period. The mean concentrations detected in the river water varied from 0.27 µg /L 
(metronodazole) to 4.66 µg /L (sulfamethoxazole). Significant (p < 0.05) seasonal and spatial 





Figure 4. Concentrations of antibiotic residues measured in waters of the Kshipra river in India in various seasons 
and at various sites over a 3-year period. 
Note: Significant (p < 0.05) seasonal and spatial variations in the occurrence of sulfamethoxazole and ofloxacin 
were found over a 3-year period.  
 
Antibiotic resistant E. coli were present in water and sediment during various seasons and at 
various sampling sites over the 3-year period. In water, significant (p < 0.05) seasonal and spatial 
variations in the resistance of E. coli to ampicillin, cefepime, amikacin, tetracycline, meropenem, 
nalidixic acid, co-trimoxazole, and sulfamethizole were found (Figure 5). There were significant 
seasonal and spatial variations in the occurrence of multidrug resistant (MDR) E. coli. In E. coli 
from sediment samples, significant (p < 0.05) seasonal and spatial variations in the resistance 
were found for ampicillin, cefotaxime, ceftazidime, meropeneme, and nitrofurantoin. There were 
significant seasonal and spatial variations in the occurrence of extended spectrum β-lactamase 
(ESBL) and MDR E.coli. Antibiotic resistance genes detected in resistant E. coli isolated from 
water and sediment samples of the river. Most E. coli isolates from both river water and sediment 




Figure 5. Antibiotic resistance patterns in E. coli isolated from water samples of the Kshipra river in India in 
various seasons and at various sites over a 3-year period.  
Note: Significant (p < 0.05) seasonal and spatial variations in the resistance of E. coli to amikacin, ampicillin, co-
trimoxazole, cefepime, meropenem, nalidixic acid, sulfamethizole, and tetracycline were found over a 3-year 
period.  
Abbreviations: AK: Amikacin, AMP: Ampicillin, COT: Co-trimoxazole, CPM: Cefepime, MRP: Meropenem, 






Sulfamethoxazole was significantly correlated with water quality parameters (p < 0.05). The 
resistance of E. coli to antibiotics (e.g., sulfamethiazole, norfloxacin, ciprofloxacine, cefotaxime, 
co-trimoxazole, ceftazidime, meropenem, ampicillin, amikacin, metronidazole, tetracycline, and 
tigecycline) had varying associations with measured water and sediment quality parameters. 
5.3 In various aquatic compartments of the environment of the WPR, the SEAR, 
China, and India, a) antibiotic residues were ubiquitous, b) residual concentrations 
of some antibiotics exceeded PNECs for the development of resistance in various 
proportions of exposure, c) the highest likelihood of exceedances of antibiotic 
PNECs (up to 100%) were observed in wastewater, and WWTPs’ influents and 
effluents, d) the likelihood of exceedances of antibiotic PNECs were also observed in 
receiving aquatic environments, and e) the highest risk for the development of 
resistance in drinking water of the WPR and China was observed for ciprofloxacin 
(62.5%) (Study III) 
Studies measuring antibiotic residue concentrations in the aquatic environment have been 
reported. The systematic review included 218 studies out of 9346 screened from the WPR, 22 
studies out of 4148 screened from the SEAR, and have largely been from China (n=168) and 
India (n=15), between 2006 and 2019. In the WPR, 92 antibiotics were detected, and in the 
SEAR, 45 antibiotics were detected. The most updated and precise analytical procedure, LC-
MS/MS was used in most published studies. The overall risk of bias in the included studies were 
low. 
Antibiotic residues were detected in diverse aquatic environmental compartments of the WPR 
and SEAR. Antibiotics from various classes such as fluoroquinolones (e.g., ciprofloxacin, 
norfloxacin, and levofloxacin), macrolides (e.g., erythromycin, azithromycin, clarithromycin, 
and roxithromycin), tetracyclines (e.g., tetracycline, oxytetracycline, chlortetracycline, and 
doxycycline), β-lactams (e.g., penicillins), lincosamides (e.g., lincomycin), sulfonamides (e.g., 
sulfamethoxazole and sulfamethazine), amphenicols (e.g., chloramphenicol and florfenicol), 
glycopeptides (e.g., vancomycin), and aminoglycosides (e.g., gentamicin) were reported to be 
found in wastewater (municipal, hospital, and pharmaceutical manufacturing/industry), 
STPs’/WWTPs’ influents and effluents, and receiving aquatic environments of the WPR and 
SEAR. The most frequently detected antibiotics include fluoroquinolones, macrolides, 
tetracyclines, and sulfonamides in hospital, municipal, and industrial wastewater, and 
STPs/WWTPs of the WPR and SEAR, and azithromycin, ciprofloxacin, ofloxacin, norfloxacin, 
enrofloxacin, sulfamethoxazole, sulfamethazine, sulfadiazine, tetracycline, chlortetracycline, 
oxytetracycline, clarithromycin, roxithromycin, erythromycin, and trimethoprim in the receiving 
aquatic environments of the WPR and SEAR. 
The results from the PEHA indicated values of predicted threshold concentrations corresponding 
to different centiles (1, 5, 25, 50, 75, 95, and 99) for the EEDs of the mMECs of antibiotics. They 
also indicated the likelihood of exceedances of antibiotic PNECs, for fluoroquinolones, 
macrolides, tetracyclines, β-lactams, lincosamides, sulfonamides, amphenicols, and 
trimethoprim for the WPR and China. The analysis for the SEAR indicated the likelihood of 
exceedances of antibiotic PNECs for fluoroquinolones, macrolides, sulfonamides, and 
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trimethoprim for aquatic environments of the SEAR, and for fluoroquinolones for aquatic 
environments of India. The results are presented in Appendix 2, Appendix 3, Appendix 4, and 





















Figure 6. Environmental exposure distributions of measured environmental concentrations (MECs) in various 
aquatic environmental compartments of the Western Pacific Region (WPR) of the WHO, for: (A) ciprofloxacin; 
(B) norfloxacin; (C) ofloxacin; (D) enrofloxacin; (E) azithromycin; (F) clarithromycin; (G) erythromycin; (H) 
roxithromycin; (I) tetracycline; and (J) oxytetracycline. Vertical lines correspond to antibiotic Predicted No Effect 
Concentration (PNEC; ng/ L) for the development of antibiotic resistance. Numbers in parenthesis indicate number 








Figure 7. Environmental exposure distributions of measured environmental concentrations (MECs in various 
aquatic environmental compartments of the South East Asia Region (SEAR) of the WHO, for: (A) ciprofloxacin; 
(B) ofloxacin; (C) levofloxacin. Vertical lines correspond to antibiotic Predicted No Effect Concentration (PNEC; 
ng/ L) for the development of antibiotic resistance. Numbers in parenthesis indicate number of data points. 
 
If the 5th centiles were considered, the highest levels of predicted threshold concentrations of 
most antibiotics and the highest likelihood of exceedances of antibiotic PNECs (up to 100%) 
were observed in wastewater and WWTPs’ influents of the WPR, the SEAR, China, and India. 
In receiving aquatic environments, the likelihood of exceedances of antibiotic PNECs for the 
development of resistance was only observed for ciprofloxacin in the river water of the SEAR. 
The likelihoods of exceedances of antibiotic PNECs for the development of resistance were 
regularly observed for fluoroquinolones, macrolides, and tetracyclines in most receiving aquatic 
environmental compartments of the WPR and China. Contamination of drinking water by 
ciprofloxacin, norfloxacin, ofloxacin, erythromycin, roxithromycin, tylosin, oxytetracycline, 
doxycycline, penicillin, lincomycin, sulfamethoxazole, sulfadiazine, sulfamethazine, 
sulfamonomethoxin, sulfapyridine, and trimethoprim was found in the WPR and China. If the 
95th centiles were considered, the highest levels and likelihood of exceeding antibiotic PNECs 
(62.5%) were observed for ciprofloxacin in the drinking water of the WPR and China (no 
drinking water results were found for the SEAR and India). 
5.4 A list of priority antibiotics in various aquatic environmental compartments of 
China was developed by ranking antibiotics in descending order, based on their a) 
overall risk, b) resistance risk on environment, c) ecotoxicity risk, d) overall 
environmental risk, e) resistance risk on human health, f) toxicity risk on human 
health, and g) overall human health risk. Ciprofloxacin posed the greatest risk 
(Study IV) 
Studies measuring the antibiotic residue concentrations in the aquatic environment have been 
reported from China in 168 publications, between 2006 and 2019. Data for 41 antibiotics were 
utilised to perform the proposed approach (our unpublished data, to be published separately). 
Results from PEHA indicated values of predicted threshold concentrations corresponding to 
various centiles (1, 5, 25, 50, 75, 95, and 99) for measured environmental concentration 
distributions of the maximum reported antibiotic concentrations (ng/L) in the aquatic 
compartments of China, and the likelihood of exceedances of antibiotics of PNECs for the 
development of antibiotic resistance, PNECE for ecotoxicity, and TTC for toxicity to human 











Figure 8. Environmental exposure distributions of measured environmental concentrations (MECs) of antibiotics 
in: (A) wastewater; (B) WWTPs influents; (C) WWTPs effluents; and (D) tap/drinking water of China. Numbers in 
parenthesis indicate the number of data points. 
 
Overall and criterion ranking 
Risk antibiotic residues in various aquatic environmental compartments of China based on the 
overall, criterion and attribute utility scores are presented in Figure 9. A list of priority antibiotics 
in various aquatic environmental compartments of China was developed by ranking antibiotics 
in descending order, based on overall, criterion, and attribute utility scores of their a) overall risk, 
b) resistance risk on environment, c) ecotoxicity risk, d) overall environmental risk, e) resistance 
risk on human health, f) toxicity risk on human health, and g) overall human health risk. 




Figure 9. Potential risks of antibiotic residues in various aquatic environmental compartments of China, based on 
overall, criterion, and attribute risk utility scores (calculations made using data from publications from China 
between 2006-2019) 
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Figure 10. Ranking of risk from various antibiotics in aquatic environmental compartments of China, based on 
descending order of overall risk scores (calculations made using data from publications from China between 2006-
2019) 
 
Data gap-based ranking 
Percentage data gaps of antibiotic residues in various aquatic environmental compartments of 
China based on overall, criterion and attribute data gap scores are presented in Figure 11. A list 
of data gaps of antibiotics in various aquatic environmental compartments of China was 
developed by ranking antibiotics based on descending orders of overall, criterion, and attribute 
data gap scores of their a) overall risk, b) resistance risk on environment, c) ecotoxicity risk, d) 
overall environmental risk, e) resistance risk on human health, f) toxicity risk on human health, 








































































































































































































































































































































































Figure 11. Percentage data gaps for antibiotics in various aquatic environmental compartments of China, based on 
overall, criterion, and attribute data gap scores (calculations made using data from publications from China 
between 2006-2019) 
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Figure 12. Ranking of data gap of antibiotics in various aquatic compartments of China, based on descending order 































































































































































































































































































































































































This thesis sheds light on the environmental and human health risks of antibiotic residues and 
antibiotic resistance in various environmental compartments of the WPR and SEAR, 
particularly China and India. I also further developed methods for a quantitative environmental 
and human health risk assessment of antibiotics and a prioritisation system. Antibiotic residues 
were present in various environmental compartments of the WPR, the SEAR, China, and India 
(Study I, Study II, and Study III). Antibiotic residues and antibiotic resistant E. coli were 
present in the water and sediment of the Kshipra river in India and showed significant seasonal 
and spatial variations over a 3-year period, and had varying associations with measured water 
quality parameters. Most E. coli isolates from both river water and sediment belonged to 
phylogenetic groups A and B1 (Study II). The most frequently detected antibiotics include 
fluoroquinolones, macrolides, tetracyclines, and sulfonamides in hospital, municipal, and 
industrial wastewater, and STPs/WWTPs of the WPR and the SEAR, and azithromycin, 
ciprofloxacin, ofloxacin, norfloxacin, enrofloxacin, sulfamethoxazole, sulfamethazine, 
sulfadiazine, tetracycline, chlortetracycline, oxytetracycline, clarithromycin, roxithromycin, 
erythromycin, and trimethoprim in the receiving aquatic environments of the WPR and SEAR. 
The values of predicted threshold concentrations corresponding to different centiles for the 
EEDs of the mMECs of antibiotics, and the likelihood of exceedances of antibiotic PNECs, for 
fluoroquinolones, macrolides, tetracyclines, β-lactams, lincosamides, sulfonamides, 
amphenicols, and trimethoprim for the WPR and China were indicated. The analysis for the 
SEAR indicated the likelihood of exceedances of antibiotic PNECs for fluoroquinolones, 
macrolides, sulfonamides, and trimethoprim for aquatic environments of the SEAR, and for 
fluoroquinolones for the aquatic environments of India (Study III). The highest environmental 
risks of antibiotic residues were observed in wastewater, STPs’/WWTPs’ influents and 
effluents (Study I and Study III). Antibiotic residues appear to pose an appreciable human 
health risk (resistance and toxicity) from environmental exposure via drinking water of the 
WPR and China, and the highest risk was observed for ciprofloxacin. An ecotoxicity risk of 
antibiotic residues in the environment of China was also observed (Study III and Study IV). A 
list of priority antibiotics for China was developed by ranking antibiotics in descending order, 
based on their a) overall risk, b) resistance risk on environment, c) ecotoxicity risk, d) overall 
environmental risk, e) resistance risk on human health, f) toxicity risk on human health, and g) 
overall human health risk. Ciprofloxacin posed the greatest risk (Study IV). 
6.1 THE OCCURRENCE OF ANTIBIOTIC RESIDUES IN THE ENVIRONMENT 
OF THE WPR, THE SEAR, CHINA, AND INDIA. 
Antibiotic residues were ubiquitous in various environmental compartments of the WPR, the 
SEAR, China, and India. An enormous diversity in antibiotic residue levels and patterns was 
observed among various aquatic environmental compartments of the WPR, the SEAR, China, 
and India (Study I, Study III, and Study III). Such occurrence and variability are influenced by 
anthropogenic input such as antibiotic use; hospital, industrial, municipal, aquaculture, and  
 
44 
agricultural activities; inefficient wastewater treatment managements, and the physicochemical 
properties of the antibiotics that are reviewed below. 
6.1.1 Antibiotic use 
The antibiotic use in human and veterinary medicines is widely regarded as a major driving 
force in the presence of antibiotic residues in the environment (7, 131). A WHO report on the 
surveillance of antibiotic consumption in humans in 2015 showed notable variation in the total 
amount and type of antibiotics consumed between the countries within the regions. In most of 
the countries of the WPR, the most frequently used antibiotic classes were β-lactams, 
quinolones, macrolides, and tetracyclines. In the SEAR, the analysis of the different classes of 
antibiotics found a high level of consumption of quinolones in some of the countries (132). The 
consumption patterns of antibiotics in the WPR and the SEAR are reflected in their presence 
in various compartments of the environment, similar classes of antibiotics have been found in 
the aquatic environment of these regions (Study III). 
6.1.2 Hospital, industrial, municipal, aquaculture, and agricultural activities 
The occurrence of antibiotic residues in the environment can be attributed to hospital, 
industrial, municipal, aquaculture, and agricultural activities. High levels of sulfamethoxazole, 
norfloxacin, and ofloxacin were detected at site 2 (Khan) of the Kshipra river. Site 2 (Khan) is 
dominated by agricultural activities and is located on the banks of the river Khan, a sub-
tributary of the Kshipra river. The Khan river brings pollutants from pharmaceutical industries 
nearby. The Khan is the major contributor of the contamination and degradation of the water 
quality of the Kshipra river (133) (Study II). Findings from Study III showed that high levels 
of antibiotic residues were typically associated with aquatic compartments routinely receiving 
urban wastewater discharge; high levels of antibiotics were found in the Haihe River, China, 
especially the sulfonamides, tetracyclines, and macrolides (134). High concentrations of 
antibiotics, including fluoroquinolones, in surface, ground, and drinking water were reported 
from Hyderabad, India, and the study suggested that the area in the vicinity of pharmaceutical 
plants was highly prone to antibiotic contamination, especially when WWTPs were inefficient 
(31). Detection of antibiotic residues in drinking water impacted by wastewater discharge has 
also been reported in the WPR and SEAR (29, 135, 136). For example, fluoroquinolones, 
including ciprofloxacin, were reported with considerably high concentration in the drinking 
waters of China (137, 138). 
6.1.3 Inefficient wastewater treatment managements 
Wastewater and STPs/WWTPs act as a major source and primary pathway for environmental 
contamination of antibiotic residues in the WPR, the SEAR, China, and India (Study III). The 
concentrations of antibiotic residues in STPs’/WWTPs’ influents and effluents, and eventually 
in the receiving aquatic environment show significant spatial and temporal variations. For 
instance, in the STPs/WWTPs, antibiotics may mainly undergo biodegradation or sorption onto 
the activated sludge and transformation and precipitation, depending on the technology used in 
the STPs/WWTPs. The removal efficiencies were highly variable for different antibiotics and 
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different STPs/WWTPs. The conventional treatment plants often did not completely remove 
the antibiotics, consequently antibiotics could still be detected in the treated wastewater 
(effluents) (139–144). Whereas advanced wastewater treatment processes can generally 
achieve higher removal rates for antibiotics compared with conventional treatment (145). 
Treatment plants are, however, a major challenge in these regions, because of the intensive 
investment and associated high cost needed. According to a 2017 United Nations report, the 
most common constraint in Asia is the lack of the human and financial resources needed to 
enforce environmental regulations and develop water services and infrastructure (146). 
6.1.4 Physicochemical properties of antibiotics 
The persistence of antibiotic residues in the aquatic environment is determined by their 
physicochemical properties such as their degradation and their sorption to organic particles 
(147, 148). Various factors affect these processes, such as the half-life; water quality (149); 
seasons (150,151); and characteristics of the soil (152). A variety of degradation processes 
may occur in the environment like hydrolysis, photo-degradation by sunlight, and 
biodegradation by bacteria under aerobic and anaerobic conditions (147). Some of the 
antibiotics are easily degraded, such as β-lactams, while others are more stable, such as 
fluoroquinolones and tetracyclines, allowing them to persist longer in the environment, to 
spread further, and accumulate in higher concentrations (153–155). Further, the mobility and 
transport of antibiotic residues in the environment depend on their sorption behaviour. 
Sulfamethoxazole is characterised by a high water solubility and is found to be the most 
persistent sulfonamide in water, with a low biodegradability and a high transport propensity  
(156) (Study I, Study II, and Study III). 
6.2 POTENTIAL ENVIRONMENTAL RISK OF ANTIBIOTIC RESISTANCE 
DEVELOPMENT 
The findings from Study III demonstrate that residual concentrations of some antibiotics 
exceeded the thresholds for the development of resistance (PNECs) in various aquatic 
environments of the WPR, the SEAR, China, and India. The highest environmental risks of 
antibiotics were observed in wastewater, and STPs’/WWTPs’ influents and effluents. In Study 
I, high and moderate environmental risks of some antibiotics were observed in wastewater of 
China. Wastewater and STPs/WWTPs served as major reservoirs of antibiotic residues, 
antibiotic resistance, and hot spots for the selection and spread of antibiotic resistance (157). 
Further, wastewater and STPs/WWTPs act as a dominant emission pathway for the release of 
antibiotic resistant bacteria and resistance genes to the receiving aquatic environments such as 
drinking water. 
Findings from Study II showed that river pollutants deteriorate and alter water quality, affecting 
the occurrence and the level of antibiotic residues in the river water. Water quality might 
contribute to the persistence of antibiotic residues in aquatic environments. Antibiotics that 
persist in the environment may therefore pose a risk with respect to antibiotic resistance 
development (158). Furthermore, it might cause a shift in the bacterial community composition 
 
46 
(159, 160). In addition, the bacterial community influences the shaping, abundance, and 
diversity of antibiotic resistance (161). Rivers are important reservoirs of antibiotic resistance 
genes where the exchange and transfer of genes can take place among pathogenic and 
commensal E. coli strains. Therefore, the resistant pathogenic E. coli load will increase, and if 
this results in infection, the disease will be more difficult to treat. The majority of the E. coli 
isolates from the Kshipra river water and sediment belong to commensal phylogenetic groups 
A and B1. There is an association between phylogenetic groups and the host species; human 
commensal strains belong mostly to groups A and B1, and strain isolates from animals fall 
mostly in group B1. The presence of phylogenetic groups A and B1 can be thus considered an 
indicator of anthropogenic activities (162). The environmental dissemination of antibiotic 
resistant bacteria and resistance genes has been of the emerging contaminants. 
6.3 POTENTIAL HUMAN HEALTH RISK OF ANTIBIOTIC RESIDUES 
Findings from Study I and Study III showed that the contamination of drinking water by 
antibiotic residues was found in the WPR and China. Antibiotic residues appear to pose 
resistance and toxicity risk to human health from environmental exposure via drinking water 
of the WPR and China, and the highest risk was observed for ciprofloxacin (Study III and Study 
IV). The human exposure to antibiotic residues or directly to antibiotic resistant bacteria via 
contaminated drinking water could increase the potential human or population health risks of 
infections with antibiotic resistant bacteria. Dissemination of resistant bacteria can also occur 
between individuals, which can further increase the prevalence of antibiotic resistance in a 
population. Drinking water has been a significant vehicle for the spread of antibiotic resistant 
bacteria and resistance genes in different countries (163). Antibiotic resistance may cause 
outbreaks of bacterial infections (164–166). Furthermore, the population density is one of the 
important factors in increasing the prevalence of antibiotic resistance (167) and this warrants 
special attention in regions such as the WPR and SEAR, which have high population densities, 
poor health services and sanitation, and unsafe drinking water. The human health risk of 
exposure to antibiotic resistance through drinking water is not only a risk to human individuals, 
but to the human population. The emergence of antibiotic residues and resistance in drinking 
water further emphasises the need to place these threats to humans in perspectives of 
environmental and health policy. 
The disruption of the human commensal gut microbiome by exposure to antibiotics can affect 
human health in the long-term and can promote long-term disease. In addition, the potential 
combined adverse effects resulting from chronic exposure to antibiotic mixtures that can be 
formed in the aquatic environments and during the treatment processes used in the WWTPs 
remain as significant knowledge gaps. Further, the potential human health risk via different 
exposure/transmission routes have not been assessed yet. This is of special concern in the case 
of the countries in the WPR and SEAR, which use aquatic systems such as rivers and lakes for 
bathing and washing and as source waters for drinking water supplies. Antibiotic contaminants 
and antibiotic resistance in drinking water should always be considered as a priority for 
management and control, to ensure negligible risks to public health. 
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6.4 PRIORITISATION OF ANTIBIOTICS FOR ECO-PHARMACOVIGILANCE 
AND HEALTH POLICY DECISIONS 
I developed an integrated environment–human risk approach for the quantitative environmental 
and human health risk assessment of antibiotic residues and a risk based prioritisation system 
thereof (Study IV). This approach addressed two main issues in an integrated manner: first, the 
potential environmental risk of antibiotic residues including the resistance risk and the 
ecotoxicity risk; and second, the potential human health risk of antibiotic residues 
encompassing the resistance risk and toxicity risk. In addition, it considered the complexity of 
environmental exposure pathways associated with antibiotic residue risks and the large 
uncertainty in the input data for these pathways, in order to prioritise risks and guide decision-
making. The outcome from this research can be used to implement eco-pharmacovigilance and 
to develop targeted policies which would prevent and minimise the environmental and human 
health risks of antibiotic residues. The utility of the approach and the system was demonstrated 
using data from China as an example. The proposed approach can be used for any other 
country/region/setting. A list of priority antibiotics from different classes such as 
fluoroquinolones, macrolides, tetracyclines, β-lactams, lincosamides, sulfonamides, 
amphenicols, and trimethoprim for China was developed. Ciprofloxacin posed the greatest risk. 
The use of this list of priority antibiotics will allow for a country/region/setting to a) optimise 
the use of antibiotics and their prescribing practices, b) effectively mitigate and monitor 
strategies, c) minimise the discharge of antibiotic residues, and d) help focus research efforts. 
As a whole, the knowledge generated in this thesis can help decision-makers to make better 
decisions and to undertake well-directed actions towards monitoring and mitigating antibiotic 
residues and antibiotic resistance, and to implement eco-pharmacovigilance (Study I, Study II, 
Study III, and Study IV). Antibiotic residues can be targeted to wherever there appears to be a 
high risk of the development of resistance within the aquatic environments of the WPR, the 
SEAR, China, and India. The findings also allow the risk manager and risk assessor to decide 
the desired level of protection based on the proportions of exposure impacted. The proposed 
approach can be used for any other country/region/setting to derive special risk reduction 
measures and to focus mitigations towards priority antibiotics and high-risk sites, and focus 
research efforts, provided the likelihood of exceedances of each antibiotic PNECs, PNECE, and 
TTC, for every aquatic environmental compartment and its threshold concentration, both 
overall and criterion risk utility scores and both overall and criterion uncertainty scores, and 
data unavailability for exposures data for every compartment and environmental risk data 
(NOEC, EC50, PNECs, PNECE, and LogKow) were specified. As such, this has the potential 
to assist policymakers in efficiently allocating resources, which is especially vital for resource-
poor settings e.g., in the WPR and SEAR (Study III and Study IV). 
6.5 METHODOLOGICAL CONSIDERATIONS 
The studies in this thesis used various methods: quantitative methods (Study I and Study II), 
microbiological and molecular methods (Study II), systematic review (Study III) and risk 




The occurrence of antibiotic residues in the environment of rural Shandong province, China 
was investigated. Samples from various environmental compartments of a reasonably large 
number of villages (12 villages) were evaluated (Study I). In order to monitor antibiotic 
residues and antibiotic resistant E. coli in the Kshipra river in India long-term, water samples 
from the river were collected in duplicate from seven selected sites during four seasons for 
three consecutive years. Sediment samples were also collected from the same seven sites. In 
addition, different water and sediment quality parameters were examined (Study II). For both 
Study I and Study II, samples were stored, protected, and transferred for analysis and analysed 
using appropriate standard methods. The most updated and precise analytical procedure, 
HPLC–MS/MS, was used to determine the concentration of antibiotic residues. The analytical 
methods are crucial for generating high precision data on antibiotic residue levels in the aquatic 
environment and for the consequent determination of the environmental and human health risk 
associated with exposure to them (168–170). Furthermore, antibiotic susceptibility testing was 
conducted following CLSI guidelines (113). 
Study III used a systematic review of the literature published between 2006 and 2019 to 
investigate all reported antibiotic residue concentrations from various aquatic environmental 
compartments of the WPR and SEAR. The overall risk of bias in the included studies were 
low. Literature indicated that LC-MS/MS was used in most studies. A large number of 
antibiotics were evaluated, 92 antibiotics in the WPR, and 45 antibiotics in the SEAR. PEHA 
does not generate a single point estimate, but rather produces a likelihood and range that a 
particular exposure and effect will occur. Accordingly, this type of assessment allows the risk 
assessors or decision-maker to conduct the assessment independent of most value judgments, 
to predict the likelihood that a certain level of protection would be attained. PEHA also permits 
the characterisation of uncertainty and variability, which can help inform decisions. 
In Study IV, the proposed approach enables the researcher to assess and quantify the 
environmental risks (resistance and ecotoxicity) and the human health risks (resistance and 
toxicity) regarding the chronic exposure of maximum concentrations of antibiotics in the 
various aquatic environmental compartments in various proportions of exposure. It also 
permits the analysis of uncertainty. 
6.5.2 Limitations 
Relatively few antibiotics and samples were analysed due to financial constraints (Study I and 
Study II). For the assessment of the risk, the MICs are derived from in vitro experiments and 
are not necessarily representative of the concentrations at which effects are expected in more 
complex systems in the environment. Studies on MSCs in complex microbial communities are 
scarce and further experimental validation are necessary to evaluate how well the PNECs 
estimate the potential for antibiotic resistance development and selection. Furthermore, some 
parameters derived from the U.S. population were applied, as Chinese data was not available 
(Study I), this can affect the estimate of the risk. 
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Study III was subject to some degree of uncertainty resulting from non-availability of a very 
exhaustive data from many of the countries in the region; the lack of data on the environmental 
occurrence of antibiotic residues for some antibiotics and compartments (studies analysed few 
antibiotic compounds); the lack of data on PNECs for the development of resistance for some 
important antibiotics such as chlortetracycline and most sulfonamides (although the EUCAST 
database have MIC data on most clinically relevant species, most environmental bacterial 
species cannot be cultivated and thus have unknown MICs); and the extrapolation of in vitro 
bacterial susceptibility data to the field conditions with complex microbial communities under 
different antibiotic exposure, and variability or heterogeneity e.g., sites, seasons, rural and 
urban area, upstream and downstream conditions, water quality, different analysed antibiotic 
compounds, characteristics of the environmental compartment, regulations, and sampling and 
analytical methods. Uncertainty and variability have the potential to result in overestimates or 
underestimates of the risk. Further, the maximum measured concentrations were used, which 
is a conservative assumption and that would overestimate the risk. In addition, there may be a 
publication bias among the included studies. Studies with a full text which could not be 
retrieved by any resource available were excluded, introducing a degree of selection bias to the 
review. This might challenge the definitive conclusions that can be drawn. However, the use 
of a relatively large number of included studies (218 from the WPR and 22 from the SEAR) in 
the analysis might mitigate this problem. 
In Study IV, data on the environmental occurrence of antibiotic residues for some antibiotics 
and compartments, NOEC, EC50, PNECs, and PNECE were not available thus, the prioritisation 
of these antibiotics was limited. Assumptions were intentionally selected to be conservative 
and that would overestimate rather than underestimate risk for a chronic lifetime exposure via 
drinking water ingestion: For this case study, the maximum measured concentrations were 
used, which is a conservative assumption, and the TTC is a conservative approach. 
6.5.3 Generalisability and transferability 
For the type of environmental research in general, the findings are very specific to the context. 
For instance, the occurrence of antibiotic residues and resistance in the environment is very 
related to the context because it is based on various factors such as the drivers, environmental 
condition, seasons, sites, and policies. Although the findings are context-specific, the methods 
used could be transferred and adapted in other contexts (Study I, Study II, and Study III). 
However, the WPR and SEAR are the largest and most populous of the WHO regions and 
include 48 countries with 53% of the world’s total population and also include countries across 
the spectrum of all income groups like High, Medium, and Low. The findings from Study III 
therefore provide many insights and are likely to be relevant to other settings also. The utility 
of the proposed approach and the system was demonstrated using data from China as an 
example. The results and discussion are focused on China, however, the approach can be used 
for any other country/region/setting and in that case, the context, results, and various eco-





 Antibiotic residues were present in various environmental compartments of Shandong 
province of China. Risk estimates indicated a potential for the measured levels of 
enrofloxacin, levofloxacin, and ciprofloxacin in wastewater to pose an environmental 
risk for resistance selection. The investigated antibiotics did not appear to pose an 
appreciable direct human health risk from environmental exposure through drinking 
water or vegetables consumption. However, they might still pose a risk for resistance 
development. 
 
 Antibiotic residues and antibiotic resistant E. coli were present in the water and 
sediment of the river in India and showed significant seasonal and spatial variations 
over a 3-year period, and had varying associations with measured water quality 
parameters. 
 
 A novel assessment of the health risk due to the antibiotic residues in the aquatic 
environment of the WPR, the SEAR, China, and India were presented. There is 
evidence that antibiotic residues were ubiquitous, and residual concentrations of some 
antibiotics exceeded the thresholds for the development of resistance in various 
proportions of exposure in various aquatic environments. Wastewater and WWTPs 
serve as a hot spot for the development of antibiotic resistance in these regions. 
Antibiotic residues appear to pose an appreciable human health risk from 
environmental exposure via drinking water. This can aid in developing effective 
monitoring and mitigation measures to combat antibiotic resistance, and to protect 
environmental and human health. 
 
 I developed an integrated environment–human risk approach, for the quantitative 
environmental (resistance and ecotoxicity) and human health (resistance and toxicity) 
risks assessment of antibiotic residues in the aquatic environment and a prioritisation 
system thereof. The utility of the approach and the system was demonstrated using data 
from China as an example and a list of priority antibiotics from different classes was 
developed. Ciprofloxacin posed the greatest risk. The proposed approach could be 
customised for other settings. Thus, the outcome from this research can be used to 
implement eco-pharmacovigilance, to develop collective actions and targeted policies 
which would prevent and minimise the environmental and human health risks of 






8 RECOMMENDATIONS FOR RESEARCH, PRACTICE, 
AND POLICY 
The emergence of antibiotic residues and antibiotic resistance in the environment caused by 
human actions and inactions show how their defined and measurable risks can influence our 
health and the environment. This requires collective actions and a sustained integrated One 
Health response with shared vision and goals. The findings in this thesis provide several 
suggestions of multipronged strategies to reduce their impact on human health and the 
environment in the WPR and SEAR and also to some extent for any other setting in general. 
These include: 
8.1 STRENGTHENING SURVEILLANCE AND MONITORING SYSTEMS 
Strengthening surveillance and systematic evidence generation regarding antibiotic residues, 
antibiotic resistant bacteria, and resistance genes in wastewater, drinking water, and food to 
pursue policymakers to implement stringent regulations. 
The implementation of One Health surveillance systems, such as the analysis of integrated 
surveillance data to ensure that data is used as a guide for responses at the country and regional 
levels, and supporting global-level surveillance through initiatives such as the WHO Global 
Antimicrobial Resistance Surveillance System (GLASS) and surveillance work undertaken by 
OIE and FAO. 
8.2 IMPROVING WASTEWATER TREATMENT MANAGEMENT SYSTEMS 
The development of cost-effective, efficient, and sustainable wastewater treatment systems 
such as off-grid and decentralised water treatment to reduce antibiotic residues and the 
antibiotic resistance burden in water sources.  
The development of an additional or a specialised drinking water treatment management 
system to reduce the very low concentrations of antibiotic residues in drinking water. 
8.3 IMPLEMENTATION OF ECO-PHARMACOVIGILANCE 
SYSTEMATICALLY 
The implementation of eco-pharmacovigilance systematically by countries in their health 
systems and to consider it in their selection of essential medicines list, their recommendations 
for prescription practices of antibiotics, their drinking water and food management systems, 
and also regulations for their pharmaceutical industries, will allow to optimise the use of 
antibiotics, to effectively prevent and reduce the environmental and human health risks of 
antibiotic residues and antibiotic resistance, to increase the compliance with risk mitigation 
measures and the verification and follow up with their implementation, and to increase the 
transparency and availability of environmental data for antibiotics. 
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8.4 ENFORCEMENT OF REGULATIONS 
Regulations of pharmaceutical industries and hospitals concerning the discharge of antibiotics 
into the environment, of hazardous industrial wastes, and of antibiotic residues and antibiotic 
resistance in drinking water and food. The implementation of incentives for various 
stakeholders for implementing the strategies for reducing the antibiotic resistance burden.  
The development and implementation of a circular economy model for industries, hospitals, 
municipals, and farmers to reduce the antibiotic residues and antibiotic resistance in effluents. 
8.5 FURTHER INVESTIGATIONS 
Research could further address what specific human health impacts are associated with 
exposure to antibiotic residues, their mixtures, interaction through various exposure routes, 
including drinking water, food consumption, inhalation, and dermal contact, to understand the 
significant relationship between antibiotic residues exposure and the human microbiome. 
Research should determine the thresholds of microbiological ADIs of antibiotics for the 
disruption of the human intestinal microbiome and the selection of resistance, the microbial 
thresholds of antibiotics for significant human antibiotic resistant bacteria development, the 
PNECs thresholds of some antibiotics for resistance development in the environment, and the 
PNECE of some antibiotics for ecotoxicity in order to perform environmental and human health 
risk assessment. 
The development of easily degradable antibiotics (171), compounds that trigger the antibiotic 
degradation  (172–174),  systems to target an antibiotic to the infection point (175), and 
adsorbents (some already in Phase II of development) that remove antibiotics from the human 
gut or in the water would all help reduce selective pressure on the human microbiome (176) or 
the environmental bacteria (177). Biorestoration of antibiotic-susceptible bacteria to remove 
resistant bacteria and control antibiotic resistance (178–183). Some of these approaches are 
still in their infancy, and further research is needed to see what their contribution might be. 
8.6 ACCELERATING THE DEVELOPMENT AND IMPLEMENTATION OF THE 
NATIONAL AND GLOBAL ONE HEALTH ANTIMICROBIAL RESISTANCE 
ACTION PLAN 
Building and sustaining effective and tailored national responses through increased political 
commitment and more integrated collaborated multi- or transdisciplinary efforts including 
human and veterinary medicine, agriculture, finance, environment, industry, scientists, 
farmers, and consumers across the One Health spectrum. 
Integrated multi-level actions in optimising antibiotic use in human and veterinary medicine, 
crop protection, and aquaculture. Strengthening key national systems for vaccination; infection 
prevention and hygiene in health care and farming settings; and integrated laboratory systems 
for human health, animal health, and the environment. Prioritising interventions and actions 
that are specific to the national context, infrastructure, and capacity. Strengthening 
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Appendix 1. An illustration of steps for calculating rank scores using ciprofloxacin as a representative antibiotic in 
aquatic environment of China (Study IV) 
Ciprofloxacin 






Resistance risk (Percentage  
Exceedance PNEC (%)) 
River water 42.5% =42.5/100=0.425 0  
Lake water 18.18% =18.18/100=0.1818 0  
Ground water 37.5% =37.5/100=0.375 0  
Sea water 62.5% =62.5/100=0.625 0  
Other water compartments 33.33% =33.33/100=0.3333 0  
Wastewater 85.71% =85.71/100=0.8571 0  
WWTPs influent 77.77% =77.77/100=0.7777 0  
WWTPs effluent 30.76% =30.76/100=0.3076 0  
Overall utility score  
                   
 










Ecotoxicity (Percentage  
Exceedance  PNECE (%)) 
    
River water 10% =10/100=0.1 0  
 
72 
Lake water 9.09% =9.09/100=0.0909 0  
Ground water 12.5% =12.5/100=0.125 0  
Sea water 0% =0/100=0 0  
Other water compartments 16.66% =16.66/100=0.1666 0  
Wastewater 57.14% =57.14/100=0.5714 0  
WWTPs influent 0% =0/100=0 0  
WWTPs effluent 0% =0/100=0 0  
Overall utility score 
                   
 
 
 =(1/8)×(0.1)+(1/8)×(0.0909)+ (1/8)×(0.125)+(1/8)×(0)+ 
(1/8)×(0.1666)+(1/8)×(0.5714)+ (1/8)×(0)+(1/8)×(0)=0.131 
  




Bioaccumulation 0.28 0 0 1 if LogKow>4.5 and 0 if 
LogKow<4.5 
Overall utility score 
                   
 =(½)× 0=0   
Uncertainty score   = (1/2)×0=0  
Ecotoxicity risk overall score  =(1/2)×(0.131)+(1/2)×(0) 
=0.065 
  
Ecotoxicity risk uncertainty score   =(1/2)×(0)+(1/2)×(0) 
=0 
 
Environmental risk overall score  =(1/2)×( 0.4853)+ (1/2)×( 0.065)=0.2751   
Environmental risk uncertainty score   =(1/2)×(0)+(1/2)×(0)=0  
 
Human health risk 
 
Resistance risk (Percentage  
Exceedance PNEC (%)) 
Drinking water 62.5% =62.5/100=0.625 0  
Ground water 37.5% =37.5/100=0.375 0  
Overall utility score  =(½)× (0.625)+(½)× (0.375)=0.5   
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Uncertainty score   =(1/2)×(0)+(1/2)×(0) 
=0 
 
Toxicity risk (Percentage  
Exceedance TTC (%)) 
Drinking water 62.5% =62.5/100=0.625 0  
Ground water 37.5% =37.5/100=0.375 0  
Overall utility score  =(½)×(0.625)+(½)×(0.375)=0.5   
Uncertainty score   =(1/2)×(0)+(1/2)×(0) 
=0 
 
Human health risk overall score  =(1/2)×( 0.5)+ (1/2)×(0.5)=0.5   





Overall utility score  = (1/2)×( 0.275)+ (1/2)×( 0.5)=0.387   
Overall uncertainty score   =(1/2)×(0)+(1/2)×(0)=0  
 
Abbreviations: PNEC: predicted not effect concentration for the development of antibiotic resistance, PNECE: predicted no effect concentration for ecotoxicity, WWTPs: 
wastewater treatment plants, Kow: octanol/water partitioning coefficient, TTC: threshold of toxicological concern. 










Appendix 2. Values of equations for regression analysis and values corresponding to various centiles for measured 
environmental concentration distributions of the maximum reported antibiotic concentrations (ng/L) in aquatic 
compartments of the Western Pacific Region of the WHO, and percentage exceeding a predicted no effect 
concentration (PNEC) for the development of antibiotic resistance (Study III) 
Western Pacific Region of the WHO 











1% 5% 25% 50% 75% 95% 99% 
Ciprofloxacin River water 46 0.929 1,205 -2.052 0.592 2.177 13.905 50.455 183.083 1169.306 4300.151 64 43.48 (20/46) 
Lake water 12 0.853 1.013 -1.461 0.140 0.658 5.976 27.685 128.258 1164.114 5479.541 64 25 (3/12) 
Drinking water 8 0.877 0.852 -1.475 0.100 0.632 8.701 53.854 333.331 4589.866 28951.823 64 62.5 (5/8) 
Ground water 10 0.85 0.698 -0.989 0.012 0.115 2.822 26.116 241.670 5935.117 56205.919 64 30 (3/10) 
Sea water 8 0.915 1.8 -3.279 3.383 8.088 27.987 66.323 157.175 543.844 1300.416 64 62.5 (5/8) 
Other water 
compartments 
8 0.934 1.004 -1.866 0.348 1.661 15.373 72.205 339.132 3139.541 14984.605 64 37.5 (3/8) 
Wastewater 12 0.965 0.727 -2.658 2.859 24.751 534.99 4530.238 38361.216 829169.327 7178758.530 64 91.67 (11/12) 
WWTPs influent 14 0.808 0.843 -2.251 0.814 5.236 74.151 467.978 2953.465 41823.072 269049.014 64 85.72 (12/14) 
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WWTPs effluent 20 0.791 0.977 -1.805 0.293 1.459 14.359 70.387 345.033 3396.786 16928.006 64 40 (8/20) 
Norfloxacin River water 44 0.914 1.128 -2.052 0.571 2.296 16.642 65.940 261.277 1893.880 7612.268 500 9.09 (4/44) 
Lake water 9 0.949 1.167 -1.666 0.272 1.043 7.073 26.767 101.289 687.170 2636.544 500 0 (0/9) 
Drinking water 8 0.985 1.213 -1.657 0.281 1.023 6.456 23.229 83.577 527.298 1922.566 500 0 (0/8) 
Ground water 10 0.890 0.751 -1.444 0.067 0.540 10.584 83.709 662.052 12971.420 104818.172 500 20 (2/10) 
Sea water 15 0.885 0.941 -1.614 0.175 0.927 9.964 51.903 270.381 2905.235 15395.888 500 13.34 (2/15) 
Wastewater 10 0.922 0.735 -2.146 0.568 4.807 100.47 831.243 6877.032 143755.339 1215701.743 500 50 (5/10) 
WWTPs influent 14 0.978 2.215 -6.022 46.609 94.654 259.55 523.282 1054.984 2892.900 5874.972 500 57.14 (8/14) 
WWTPs effluent 21 0.889 2.168 -4.676 12.128 25.011 70.100 143.492 293.723 823.233 1697.717 500 14.29 (3/21) 
Ofloxacin River water 49 0.982 1.205 -2.25 0.864 3.178 20.299 73.658 267.278 1707.040 6277.678 500 16.33 (8/49) 
Lake water 13 0.943 1.222 -1.634 0.271 0.980 6.098 21.735 77.465 482.155 1741.301 500 7.69 (1/13) 
Drinking water 7 0.774 1.382 -1.923 0.511 1.590 8.006 24.630 75.773 381.645 1187.904 500 0 (0/7) 
Ground water 11 0.91 0.993 -1.097 0.058 0.281 2.664 12.727 60.810 577.008 2802.078 500 9.09 (1/11) 





7 0.93 1.175 -1.488 0.193 0.735 4.924 18.466 69.250 463.723 1763.005 500 0 (0/7) 
Wastewater 9 0.95 0.653 -2.298 0.905 10.005 306.36 3304.779 35649.356 1091592.85 12069703.21 500 66.67 (6/9) 
WWTPs influent 15 0.834 1.303 -4.16 25.542 85.167 473.13 1558.233 5131.875 28509.610 95062.810 500 86.67 (13/15) 
WWTPs effluent 24 0.933 1.077 -2.544 1.593 6.837 54.431 230.206 973.608 7751.254 33276.901 500 37.5 (9/24) 
Fleroxacin River water 6 0.946 1.037 -1.380 0.122 0.555 4.790 21.417 95.760 825.900 3750.645 - - 
WWTPs effluent 10 0.955 1.642 -2.06 0.688 1.790 6.979 17.971 46.274 180.429 469.186 - - 
Lomefloxacin River water 9 0.810 1.137 -1.514 0.193 0.767 5.475 21.457 84.099 600.116 2385.694 - - 
Ground water 5 0.787 1.328 -1.482 0.231 0.754 4.056 13.061 42.059 226.234 737.449 - - 
WWTPs effluent 6 0.978 1.626 -2.226 0.868 2.277 8.999 23.389 60.788 240.214 630.553 - - 
Enoxacin River water 7 0.858 1.529 -2.383 1.089 3.039 13.104 36.186 99.923 430.830 1202.315 - - 
Nalidixic acid River water 6 0.906 3.569 -5.143 6.155 9.553 17.866 27.607 42.658 79.780 123.834 16000 0 (0/6) 
Moxifloxacin River water 5 0.819 1.398 -1.945 0.534 1.639 8.106 24.619 74.772 369.700 1135.867 125 20 (1/5) 
Enrofloxacin River water 31 0.797 0.806 -1.198 0.040 0.279 4.462 30.644 210.469 3365.997 23585.226 64 35.48 (11/31) 
Lake water 9 0.934 1.278 -1.294 0.156 0.531 3.053 10.292 34.697 199.330 680.492 64 22.22 (2/9) 
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Ground water 8 0.656 0.794 -1.194 0.037 0.271 4.511 31.899 225.560 3761.685 27144.853 64 25 (2/8) 
Sea water 8 0.847 1.085 -1.729 0.281 1.196 9.373 39.224 164.134 1286.893 5465.725 64 25 (2/8) 
Other water 
compartments 
8 0.922 0.955 -1.387 0.104 0.537 5.573 28.337 144.088 1495.257 7732.544 64 25 (2/8) 
Wastewater 8 0.911 0.691 -2.49 1.725 16.714 424.01 4013.038 37982.186 963538.814 9334965.078 64 100 (8/8) 
WWTPs influent 9 0.971 1.485 -2.193 0.813 2.339 10.533 29.976 85.304 384.073 1104.923 64 22.22 (2/9) 
WWTPs effluent 15 0.925 1.622 -2.025 0.652 1.715 6.802 17.720 46.163 183.041 481.621 64 13.33 (2/15) 
Sarafloxacin WWTPs effluent 5 0.833 2.170 -1.106 0.274 0.565 1.581 3.234 6.615 18.521 38.170 - - 
Difloxacin River water 6 0.950 1.100 -1.520 0.185 0.770 5.870 24.089 98.853 753.598 3138.195 - - 
Lake water 5 0.967 0.960 -1.013 0.043 0.220 2.252 11.356 57.253 586.945 3009.452 - - 
Flumequine River water 7 0.796 1.745 -1.932 0.594 1.461 5.256 12.799 31.167 112.143 275.622 250 0 (0/7) 
Azithromycin River water 21 0.941 1.293 -1.853 0.430 1.449 8.156 27.108 90.105 507.251 1707.213 250 9.52 (2/21) 
Lake water 6 0.981 2.074 -2.576 1.319 2.812 8.257 17.460 36.920 108.424 231.056 250 0 (0/6) 
Sea water 8 0.899 0.804 -0.642 0.008 0.057 0.911 6.288 43.394 698.788 4920.112 250 12.5 (1/8) 




WWTPs effluent 11 0.872 1.309 -3.068 3.686 12.224 67.376 220.686 722.845 3984.250 13212.001 250 63.63 (7/11) 
Clarithromycin River water 29 0.977 1.061 -1.438 0.145 0.638 5.243 22.663 97.957 804.658 3531.218 250 17.24 (5/29) 
Lake water 6 0.923 1.536 -1.737 0.413 1.148 4.917 13.516 37.152 159.121 441.986 250 0 (0/6) 
Sea water 9 0.846 1.155 -0.283 0.017 0.066 0.458 1.758 6.745 46.681 181.625 250 0 (0/9) 
Other water 
compartments 
10 0.949 0.945 -1.049 0.044 0.234 2.491 12.884 66.650 708.988 3730.755 250 10 (1/10) 
WWTPs influent 7 0.898 0.799 -1.91 0.301 2.147 35.182 245.747 1716.546 28127.326 200476.015 250 57.14 (4/7) 
WWTPs effluent 11 0.909 0.796 -1.619 0.129 0.928 15.366 108.123 760.797 12598.494 90462.207 250 45.45 (5/11) 
Erythromycin River water 52 0.961 1.21 -2.419 1.193 4.363 27.653 99.810 360.249 2283.267 8351.704 1000 13.46 (7/52) 
Lake water 16 0.986 0.956 -1.599 0.173 0.895 9.270 47.054 238.851 2472.591 12764.753 1000 12.5 (2/16( 
Drinking water 7 0.985 1.332 -1.659 0.315 1.025 5.484 17.599 56.477 302.253 981.755 1000 0 (0/7) 
Ground water 8 0.93 1.164 -1.892 0.423 1.631 11.117 42.211 160.283 1092.783 4207.365 1000 0 (0/8) 
Sea water 14 0.977 0.858 -0.947 0.025 0.154 2.078 12.698 77.598 1049.080 6532.671 1000 7.14 (1/14) 
Other water 
compartments 
12 0.904 0.914 -1.705 0.209 1.164 13.411 73.354 401.218 4624.318 25743.351 1000 16.66 (2/12) 
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Wastewater 7 0.915 1.005 -2.921 3.906 18.612 171.92 806.246 3780.957 34925.122 166433.852 1000 57.14 (4/7) 
WWTPs influent 17 0.600 0.686 -1.64 0.100 0.984 25.553 245.850 2365.330 61435.071 605129.343 1000 23.53 (4/17) 
WWTPs effluent 26 0.872 1.098 -2.273 0.894 3.733 28.565 117.524 483.523 3699.753 15446.903 1000 7.69 (2/26) 
Roxithromycin River water 48 0.956 1.182 -1.719 0.306 1.155 7.650 28.465 105.913 701.294 2645.210 1000 2.08 (1/48) 
Lake water 12 0.915 1.258 -1.155 0.117 0.408 2.410 8.282 28.463 168.128 585.285 1000 0 (0/12) 
Drinking water 6 0.941 1.844 -1.608 0.408 0.955 3.208 7.448 17.290 58.079 136.017 1000 0 (0/6) 
Sea water 16 0.977 0.92 -1.054 0.041 0.228 2.585 13.985 75.647 858.097 4723.796 1000 6.25 (1/16) 
Other water 
compartments 
6 0.774 1.162 -1.311 0.134 0.516 3.530 13.435 51.131 349.755 1349.733 1000 0 (0/6) 
WWTPs influent 12 0.860 1.163 -2.705 2.116 8.158 55.709 211.778 805.078 5497.951 21192.415 1000 16.66 (2/12) 
WWTPs effluent 19 0.921 1.180 -2.500 1.403 5.305 35.241 131.415 490.056 3255.276 12306.238 1000 10.52 (2/19) 
Tylosin River water 7 0.930 1.286 -1.351 0.174 0.591 3.358 11.234 37.586 213.595 723.642 4000 0 (0/7) 
Drinking water 7 0.822 1.695 -0.467 0.080 0.202 0.754 1.886 4.715 17.617 44.462 4000 0 (0/7) 
WWTPs effluent 8 0.924 1.085 -1.066 0.069 0.293 2.295 9.605 40.192 315.125 1338.406 4000 0 (0/8) 




Lake water 9 0.910 1.407 -2.269 0.910 2.777 13.592 40.987 123.604 604.925 1845.275 1000 0 (0/9) 
Ground water 6 0.939 1.771 -2.859 1.999 4.848 17.119 41.147 98.900 349.231 847.073 1000 0 (0/6) 
Sea water 11 0.939 1.220 -2.183 0.763 2.761 17.238 61.566 219.890 1372.729 4968.059 1000 9.09 (1/11) 
Other water 
compartments 
7 0.954 1.159 -2.393 1.142 4.421 30.392 116.068 443.271 3047.275 11800.859 1000 14.28 (1/7) 
Wastewater 10 0.948 0.724 -2.485 1.656 14.468 316.74 2705.954 23117.247 506078.301 4420873.757 1000 70 (7/10) 
WWTPs influent 10 0.803 1.363 -3.439 6.551 20.717 106.72 333.511 1042.240 5369.081 16978.360 1000 10 (1/10) 
WWTPs effluent 15 0.857 1.056 -1.831 0.340 1.501 12.450 54.188 235.843 1956.717 8647.338 1000 13.33 (2/15) 
Chlortetracycline River water 28 0.942 1.158 -1.932 0.457 1.770 12.188 46.601 178.178 1226.931 4756.963 - - 
Lake water 8 0.961 1.138 -1.758 0.317 1.257 8.956 35.060 137.250 977.699 3882.021 - - 
Ground water 6 0.657 0.547 -1.193 0.008 0.149 8.870 151.701 2594.526 154181.485 2715866.149 - - 
Sea water 5 0.803 0.964 -1.101 0.054 0.273 2.770 13.871 69.470 705.336 3592.031 - - 
Other water 
compartments 
5 0.916 2.457 -6.551 52.413 99.267 246.46 463.724 872.524 2166.286 4102.836 - - 
Wastewater 7 0.931 0,926 -4.058 74.137 403.64 4507.1 24115.12 129026.844 1440751.99 7844118.402 - - 
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WWTPs influent 11 0.815 0.726 -1.631 0.110 0.957 20.773 176.424 1498.324 32523.335 282418.010 - - 
WWTPs effluent 11 0.943 0.989 -1.909 0.378 1.850 17.711 85.159 409.472 3920.855 19162.620 - - 
Oxytetracycline River water 38 0.943 1.184 -2.313 0.974 3.667 24.203 89.856 333.594 2201.820 8286.443 500 15.79 (6/38) 
Lake water 7 0.846 1.035 -1.709 0.253 1.153 9.989 44.793 200.858 1739.555 7922.949 500 14.28 (1/7) 
Drinking water 7 0.887 1.877 -2.942 2.128 4.910 16.145 36.931 84.477 277.789 640.902 500 0 (0/7) 
Ground water 6 0.684 0.669 -1.403 0.042 0.435 12.273 125.072 1274.576 35961.270 375414.482 500 16.66 (1/6) 
Sea water 8 0.911 0.889 -1.890 0.323 1.887 23.296 133.655 766.815 9467.020 55309.344 500 25 (2/8) 
Other water 
compartments 
10 0.881 1.132 -2.403 1.169 4.675 33,647 132.676 523.155 3765.671 15061.532 500 20 (2/10) 
Wastewater 10 0.945 0.728 -2.992 8.210 70.872 1525.4 12879.23 108739.422 2340477.29 20203327.50 500 90 (9/10) 
WWTPs influent 11 0.938 1.192 -3.525 10.129 37.784 246.24 906.181 3334.739 21733.293 81067.893 500 54.54 (6/11) 
WWTPs effluent 16 0.952 1.345 -2.665 1.779 5.668 29.519 92.948 292.677 1524.238 4857.045 500 25 (4/16) 
Doxycycline River water 17 0.967 1.824 -2.044 0.700 1.655 5.634 13.201 30.931 105.293 248.900 2000 0 (0/17) 
Lake water 5 0.677 1.245 -2.271 0.903 3.184 19.157 66.695 232.196 1397.217 4927.753 2000 0 (0/5) 
Drinking water 5 0.800 1.226 -1.987 0.529 1.901 11.764 41.756 148.208 916.981 3297.830 2000 0 (0/5) 
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Wastewater 6 0.969 0.758 -2.255 0.805 6.382 121.65 943.917 7324.234 139612.926 1106609.914 2000 33.33 (2/6) 
WWTPs effluent 7 0.787 0.543 -1.093 0.005 0.096 5.898 103.013 1799.060 110176.180 1982173.076 2000 14.28 (1/7) 
Amoxicillin River water 5 0.954 0.979 -1.423 0.119 0.593 5.815 28.413 138.380 1360.381 6757.299 250 20 (1/5) 
Penicillin Drinking water 7 0.925 0.950 -1,421 0.111 0.581 6.107 31.318 160.612 1687.386 8801.906 64 57.14 (4/7) 
Lincomycin River water 14 0.969 1.289 -2.191 0.785 2.653 15.014 50.092 167.122 945.882 3195.485 2000 0 (0/14) 
Lake water 9 0.929 0.981 -1.324 0.095 0.471 4.593 22.369 108.942 1062.562 5260.751 2000 0 (0/9) 
Drinking water 6 0.962 1.540 -1.536 0.307 0.850 3.626 9.940 27.251 116.276 322.120 2000 0 (0/6) 
Other water 
compartments 
9 0.982 0.965 -1.754 0.255 1.297 13.142 65.708 328.526 3327.577 16917.639 2000 11.11 (1/9) 
Wastewater 5 0.902 0.740 -2.948 6.919 57.678 1181.1 9633.493 78569.940 1609010.78 13412110.63 2000 40 (2/5) 
WWTPs influent 7 0.847 0.839 -2.132 0.587 3.807 54.601 347.633 2213.306 31740.472 206007.506 20000 14.28 (1/7) 
WWTPs effluent 8 0.785 0.812 -1.759 0.200 1.382 21.657 146.641 992.907 15557.434 107452.517 2000 12.5 (1/8) 
Sulfamethoxazole River water 73 0.924 1.495 -2.813 2.116 6.045 26.943 76.139 215.164 959.051 2739.624 16000 0 (0/73) 
Lake water 20 0.974 1.237 -2.471 1.309 4.654 28.334 99.443 349.010 2124.647 7554.604 16000 0 (0/20) 
Drinking water 11 0.900 1.846 -2.486 1.220 2.855 9.579 22.218 51.532 172.875 404.488 16000 0 (0/11) 
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Ground water 9 0.938 0.942 -1.328 0.087 0.461 4.940 25.690 133.593 1431.844 7574.434 16000 0 (0/9) 
Sea water 17 0.939 1.361 -1.679 0.334 1.059 5.471 17.126 53.609 276.831 876.889 16000 0 (0/17) 
Other water 
compartments 
18 0.981 1.041 -2.067 0.563 2.544 21.760 96.737 430.047 3678.422 16607.909 16000 0 (0/18) 
Wastewater 15 0.987 0.507 -1.424 0.017 0.367 30.083 643.693 13773.142 1129706.77 24953751.52 16000 26.66 (4/15) 
WWTPs influent 26 0.947 1.027 -2.603 1.859 8.570 75.476 342.426 1553.546 13682.859 63060.078 16000 3.84 (1/26) 
WWTPs effluent 35 0.923 1.168 -2.658 1.923 7.369 49.913 188.662 713.114 4830.032 18510.627 16000 2.85 (1/35) 
Sulfacetamide River water 6 0.994 1.333 -1.126 0.126 0.408 2.181 6.994 22.424 119.856 388.963 - - 
Sulfachloropyridazine River water 12 0.930 1.680 -1.432 0.294 0.747 2.824 7.118 17.942 67.836 172.628 - - 
WWTPs influent 5 0.968 1.064 -1.522 0.175 0.767 6.259 26.943 115.977 947.035 4138.742 - - 
WWTPs effluent 7 0.972 1.058 -1.153 0.078 0.343 2.833 12.297 53.371 441.036 1943.608 - - 
Sulfadiazine River water 52 0.977 1.364 -2.247 0.875 2.763 14.219 44.398 138.629 713.288 2253.691 - - 
Lake water 15 0.923 1.112 -1.737 0.295 1.210 9.026 36.480 147.437 1099.601 4509.099 - - 
Drinking water 9 0.908 1.992 -2.533 1.270 2.792 8.570 18.689 40.755 125.117 275.063 - - 
Ground water 5 0.922 3.106 -2.920 1.553 2.574 5.284 8.712 14.364 29.491 48.877 - - 
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Sea water 15 0.940 1.100 -0.406 0.018 0.075 0.570 2.339 9.600 73.183 304.756 - - 
Other water 
compartments 
10 0.980 1.201 -1.834 0.389 1.437 9.235 33.656 122.650 788.190 2911.185 - - 
WWTPs influent 13 0.974 0.829 -1.604 0.134 0.893 13.220 86.072 560.376 8298.568 55089.777 - - 
WWTPs effluent 20 0.917 0.805 -1.430 0.077 0.541 8.680 59.758 411.408 6602.280 46373.583 - - 
Sulfadimethoxine River water 14 0.913 1.674 -1.103 0.186 0.475 1.803 4.559 11.530 43.802 111.839 - - 
Sea water 5 0.948 1.204 0.0914 0.010 0.036 0.231 0.840 3.050 19.509 71.824 - - 
WWTPs influent 7 0.969 1.034 -1.119 0.068 0.310 2.691 12.084 54.265 470.948 2148.117 - - 
WWTPs effluent 6 0.932 0.898 -0.261 0.005 0.029 0.346 1.953 11.009 132.535 760.736 - - 
Sulfadimidine River water 12 0.972 1.248 -2.243 0.857 3.015 18.064 62.701 217.637 1303.969 4584.969 - - 
Sulfamerazine River water 9 0.847 0.678 -0.599 0.003 0.029 0.774 7.647 75.562 2039.476 20638.227 - - 
WWTPs influent 7 0.976 1.541 -1.162 0.176 0.486 2.072 5.676 15.551 66.290 183.523 - - 
WWTPs effluent 10 0.880 0.966 -0.380 0.010 0.049 0.496 2.474 12.348 124.773 633.290 - - 
Sulfameter River water 11 0.946 1.103 -1.112 0.079 0.329 2.493 10.190 41.655 315.801 1309.994 - - 
Sulfamethazine River water 47 0.952 1.291 -2.205 0.805 2.716 15.329 51.048 169.994 959.557 3235.578 - - 
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Lake water 14 0.810 1.207 -0.936 0.070 0.259 1.647 5.963 21.592 137.480 504.495 - - 
Drinking water 9 0.953 1.500 -1.773 0.428 1.217 5.399 15.205 42.821 189.919 540.628 - - 
Ground water 6 0.916 1.350 -1.110 0.126 0.402 2.102 6.641 20.982 109.808 351.110 - - 
Sea water 9 0.957 1.226 -0.952 0.076 0.272 1.684 5.977 21.216 131.266 472.084 - - 
Other water 
compartments 
12 0.946 1.034 -2.127 0.642 2.926 25.395 114.041 512.119 4444.547 20272.758 - - 
Wastewater 9 0.934 0.762 -3.210 14.443 113.23 2125.40 16315.42 125243.610 2350709.62 18430978.44 - - 
WWTPs influent 16 0.900 1.047 -1.693 0.248 1.112 9.393 41.400 182.479 1541.760 6901.106 - - 
WWTPs effluent 23 0.973 0.985 -1.309 0.093 0.456 4.407 21.327 103.204 997.324 4905.785 - - 
Sulfamethizole River water 5 0.980 0.730 -0.442 0.003 0.023 0.480 4.032 33.841 722.277 6198.083 - - 
WWTPs influent 5 0.891 0.796 -0.512 0.005 0.038 0.625 4.398 30.943 512.407 3679.287 - - 
WWTPs effluent 5 0.970 1.599 -0.199 0.047 0.125 0.504 1.332 3.518 14.228 37.960 - - 
Sulfamonomethoxine River water 12 0.986 1.591 -2.622 1.534 4.113 16.752 44.465 118.021 480.694 1288.880 - - 
Lake water 6 0.818 1.206 -1.800 0.366 1.345 8.575 31.084 112.672 718.504 2639.463 - - 




Sulfapyridine River water 26 0.988 1.305 -1.743 0.357 1.189 6.588 21.659 71.200 394.509 1313.029 - - 
Lake water 8 0.962 1.184 -0.692 0.042 0.157 1.035 3.841 14.260 94.123 354.226 - - 
Drinking water 6 0.951 2.290 -0.769 0.209 0.415 1.100 2.167 4.269 11.326 22.474 - - 
WWTPs effluent 7 0.891 0.934 -1.803 0.275 1.477 16.153 85.194 449.323 4914.644 26372.016 - - 
Sulfaquinoxaline River water 12 0.969 1.884 -2.014 0.683 1.570 5.140 11.722 26.731 87.512 201.277 - - 
Sulfathiazole River water 21 0.906 1.318 -1.241 0.150 0.494 2.690 8.741 28.401 154.728 508.906 - - 
Lake water 6 0.950 1.953 -1.838 0.562 1.256 3.942 8.732 19.341 60.720 135.607 - - 
WWTPs influent 7 0.966 0.773 -1.181 0.033 0.251 4.521 33.714 251,406 4525.815 34460.325 - - 
WWTPs effluent 10 0.922 0.928 -0.762 0.021 0.112 1.243 6.624 35.314 392.276 2127.948 - - 
Trimethoprim River water 50 0.926 1.141 -2.071 0.597 2.363 16.747 65.324 254.808 1805.777 7144.010 500 22 (11/50) 
Lake water 10 0.953 1.536 -1.357 0.234 0.650 2.782 7.647 21.018 90.019 250.042 500 0 (0/10) 
Drinking water 7 0.844 2.127 -2.022 0.719 1.504 4.301 8.926 18.524 52.961 110.753 500 0 (0/7) 
Ground water 5 0.821 0.961 -0.722 0.021 0.110 1.121 5.640 28.390 290.340 1486.135 500 0 (0/5) 




Abbreviations: n: the total number of data points or studies, a: slope, b: intercept, PNEC: predicted not effect concentration for the development of antibiotic resistance, 






14 0.923 1.422 -2.480 1.282 3.866 18.608 55.465 165.328 795.685 2398.786 500 7.14 (1/14) 
Wastewater 10 0.861 0.705 -2.297 0.909 8.415 200.186 1811.991 16401.330 390195.036 3613601.409 500 60 (6/10) 
WWTPs influent 22 0.830 0.897 -2.095 0.552 3.176 38.337 216.552 1223.214 14766.941 84925.650 500 36.36 (8/22) 
WWTPs effluent 33 0.872 0.974 -1.973 0.434 2.172 21.536 106.088 522.591 5181.181 25948.656 500 21.21 (7/33) 
Thiamphenicol River water 7 0.949 0.944 -1.084 0.048 0.255 2.715 14.070 72.913 777.562 4098.799 1000 0 (0/7) 
Florfenicol River water 14 0.969 1.089 -2.176 0.728 3.074 23.922 99.578 414.505 3225.442 13626.596 2000 7.14 (1/14) 
Lake water 10 0.898 1.334 -2.942 2.894 9.384 50.094 160.471 514.058 2744.233 8897.874 2000 0 (0/10) 
Sea water 5 0.912 1.517 -1.399 0.245 0.689 3.003 8.360 23.272 101.507 285.584 2000 0 (0/5) 
Chloramphenicol River water 19 0.92 1.357 -1.66 0.323 1.026 5.324 16.722 52.521 272.528 866.200 8000 0(0/19) 
WWTPs influent 6 0.938 5.533 -9.376 18.798 24.962 37.382 49.495 65.533 98.139 130.320 8000 0(0/6) 
WWTPs effluent 9 0.986 1.552 -1.744 0.421 1.158 4.888 13.296 36.166 152.595 419.418 8000 0 (0/9) 
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Appendix 3. Values of equations for regression analysis and values corresponding to various centiles for measured 
environmental concentration distributions of the maximum reported antibiotic concentrations (ng/L) in aquatic 
compartments of the South East Asia Region of the WHO, and percentage exceeding a predicted no effect 
concentration (PNEC) for the development of antibiotic resistance (Study III) 
 
South East Asia of the WHO 











1% 5% 25% 50% 75% 95% 99% 
Ciprofloxacin River water 3 0.846 0.996 -2.091 0.580 2.805 26.436 125.718 597.855 5634.522 27232.545 64 33.33 (1/3) 
WWTPs 
influent 
4 0.984 0.823 -3.387 19.443 130.86 1976.42 13044.61 86095.702 1300284.63 8751842.279 64 100 (4/4) 
WWTPs 
effluent 
4 0.861 0.380 -1.555 0.009 0.580 207.555 12362.47 736339.825 263431338.99 16370930045.983 64 100 (4/4) 
Ofloxacin Wastewater 3 1.000 1.014 -3.933 38.412 180.53 1635.012 7563.072 34984.486 316841.340 1489110.402 500 100 (3/3) 
Levofloxacin Wastewater 3 0.989 1.219 -4.929 136.48 494.46 3091.465 11052.95 39517.754 247072.813 895127.807 250 100 (3/3) 
Roxithromycin Other water 
compartments 
3 1.000 1.646 -2.159 0.791 2.053 7.978 20.496 52.655 204.629 530.883 1000 0 (0/3) 




Abbreviations: n: the total number of data points or studies, a: slope, b: intercept, PNEC: predicted not effect concentration for the development of antibiotic resistance, 










3 0.785 1.335 -3.387 6.230 20.183 107.608 344.412 1102.337 5877.312 19039.754 16000 0 (0/3) 
WWTPs 
influent 
4 0.966 0.921 -2.660 2.303 12.654 143.159 772.974 4173.593 47218.064 259452.880 16000 0 (0/4) 
WWTPs 
effluent 
3 0.777 1.221 -2.861 2.741 9.909 61.767 220.375 786.265 4901.148 17719.120 16000 0 (0/3) 
Sulfamethazine Other water 
compartments 
3 0.832 7.063 -13.04 32.950 41.148 56.459 70.345 87.645 120.258 150.177 - - 
Trimethoprim Other water 
compartments 
3 0.975 2.571 -5.706 20.631 37.984 90.578 165.718 303.190 723.006 1331.103 500 0 (0/3) 
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Appendix 4. Values of equations for regression analysis and values corresponding to various centiles for measured 
environmental concentration distributions of the maximum reported antibiotic concentrations (ng/L) in aquatic 
compartments of China, and percentage exceeding a predicted no effect concentration (PNEC) for the development 
of antibiotic resistance (Study III) 
China 











1% 5% 25% 50% 75% 95% 99% 
Ciprofloxacin River water 40 0.944 1.148 -1.948 0.468 1.837 12.863 49.758 192.486 1347.918 5288.099 64 42.5 (17/40) 
Lake water 11 0.823 0.971 -1.346 0.098 0.492 4.915 24.333 120.458 1202.760 6053.780 64 18.18 (2/11) 
Drinking water 8 0.877 0.852 -1.475 0.100 0.632 8.701 53.854 333.331 4589.866 28951.823 64 62.5 (5/8) 
Ground water 8 0.781 0.730 -1.300 0.039 0.337 7.192 60.370 506.735 10815.487 92811.080 64 37.5 (3/8) 
Sea water 8 0.915 1.800 -3.279 3.383 8.088 27.987 66.323 157.175 543.844 1300.416 64 62.5 (5/8) 
Other water 
compartments 
6 0.924 1.022 -1.795 0.302 1.403 12.485 57.064 260.814 2321.699 10780.279 64 33.33 (2/6) 
Wastewater 7 0.971 0.575 -2.054 0.336 5.147 250.696 3733.997 55615.976 2708874.69 41495050.99 64 85.71 (6/7) 
WWTPs influent 9 0.981 2.967 -6.204 20.273 34.405 82.084 123.311 208.129 441.961 750.024 64 77.77 (7/9) 
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WWTPs effluent 13 0.976 2.045 -3.161 2.559 5.513 16.440 35.133 75.084 223.898 482.280 64 30.76 (4/13) 
Norfloxacin River water 41 0.915 1.097 -1.995 0.499 2.085 15.986 65.856 271.297 2079.730 8694.437 500 9.75 (4/41) 
Lake water 9 0.949 1.167 -1.666 0.272 1.043 7.073 26.767 101.289 687.170 2636.544 500 0 (0/9) 
Drinking water 8 0.985 1.213 -1.657 0.281 1.023 6.456 23.229 83.577 527.298 1922.566 500 0 (0/8) 
Ground water 8 0.815 0.795 -1.805 0.221 1.590 26.426 186.398 1314.786 21849.350 157276.557 500 25 (2/8) 
Sea water 12 0.914 0.879 -1.607 0.152 0.906 11.505 67.331 394.050 5006.015 29839.978 500 16.66 (2/12) 
Wastewater 6 0.760 0.562 -1.476 0.031 0.501 26.679 422.994 6706.474 357371.844 5831006.803 500 33.33 (2/6) 
WWTPs influent 13 0.980 2.197 -6.036 48.810 99.701 275.663 558.963 1133.412 3133.751 6401.144 500 61.53 (8/13) 
WWTPs effluent 20 0.888 2.130 -4.553 11.101 23.191 66.206 137.265 284.591 812.438 1697.230 500 15 (3/20) 
Ofloxacin River water 44 0.981 1.187 -2.207 0.793 2.976 19.547 72.328 267.633 1758.055 6594.231 500 15.90 (7/44) 
Lake water 12 0.930 1.361 -1.664 0.326 1.033 5.334 16.697 52.265 269.894 854.916 500 0 (0/12) 
Drinking water 7 0.774 1.382 -1.923 0.511 1.590 8.006 24.630 75.773 381.645 1187.904 500 0 (0/7) 
Ground water 9 0.901 0.983 -1.228 0.076 0.377 3.657 17.752 86.177 836.636 4128.733 500 11.11 (1/9) 





6 0.877 1.077 -1.449 0.153 0.658 5.238 22.152 93.685 745.863 3202.062 500 0 (0/6) 
WWTPs influent 16 0.942 1.956 -5.986 74.300 165.73 519.393 1149.019 2541.899 7966.259 17769.148 500 85.71 (12/14) 
WWTPs effluent 23 0.937 1.188 -2.707 2.091 7.835 51.389 189.941 702.056 4604.436 17251.418 500 34.78 (8/23) 
Fleroxacin River water 6 0.946 1.037 -1.38 0.122 0.555 4.790 21.417 95.760 825.900 3750.645 - - 
WWTPs effluent 10 0.955 1.642 -2.06 0.688 1.790 6.979 17.971 46.274 180.429 469.186 - - 
Lomefloxacin River water 8 0.789 1.145 -1.644 0.254 0.998 7.026 27.278 105.897 745.352 2934.626 - - 
Ground water 5 0.787 1.328 -1.482 0.231 0.754 4.056 13.061 42.059 226.234 737.449 - - 
WWTPs effluent 6 0.978 1.626 -2.226 0.868 2.277 8.999 23.389 60.788 240.214 630.553 - - 
Enoxacin River water 7 0.858 1.529 -2.383 1.089 3.039 13.104 36.186 99.923 430.830 1202.315 - - 
Nalidixic acid River water 5 0.949 3.322 -4.853 5.762 9.241 18.106 28.898 46.122 90.366 144.928 16000 0 (0/5) 
Moxifloxacin River water 5 0.819 1.398 -1.945 0.534 1.639 8.106 24.619 74.772 369.700 1135.867 125 20 (1/5) 
Enrofloxacin River water 30 0.786 0.800 -1.156 0.034 0.245 3.998 27.861 194.139 3170.057 22539.010 64 33.33 (10/30) 
Lake water 8 0.908 1.478 -1.272 0.193 0.559 2.537 7.255 20.748 94.084 272.023 64 12.5 (1/8) 
Ground water 7 0.615 1.522 -2.774 1.968 5.519 23.958 66.466 184.400 800.425 2244.309 64 28.57 (2/7) 
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Sea water 8 0.847 1.085 -1.729 0.281 1.196 9.373 39.224 164.134 1286.893 5465.725 64 25 (2/8) 
Other water 
compartments 
5 0.989 0.850 -0.985 0.026 0.167 2.319 14.415 89.607 1241.496 7865.084 64 20 (1/5) 
Wastewater 5 0.952 0.689 -2.871 6.173 60.201 1541.58 14686.17 139909.98 3582731.50 34939812.64 64 100 (5/5) 
WWTPs influent 8 0.971 1.393 -2.035 0.618 1.906 9.477 28.899 88.120 438.203 1351.771 64 37.5 (3/8) 
WWTPs effluent 14 0.942 1.614 -1.963 0.595 1.574 6.285 16.453 43.066 171.929 454.557 64 14.28 (2/14) 
Sarafloxacin WWTPs effluent 5 0.833 2.170 -1.106 0.274 0.565 1.581 3.234 6.615 18.521 38.170 - - 
Difloxacin River water 6 0.950 1.100 -1.520 0.185 0.770 5.870 24.089 98.853 753.598 3138.195 - - 
Lake water 5 0.967 0.960 -1.013 0.043 0.220 2.252 11.356 57.253 586.945 3009.452 - - 
Flumequine River water 7 0.796 1.745 -1.932 0.594 1.461 5.256 12.799 31.167 122.143 275.622 250 0 (0/7) 
Azithromycin River water 16 0.940 1.547 -1.945 0.567 1.563 6.626 18.083 49.348 209.183 576.836 250 0 (0/16) 
Lake water 5 0.982 2.698 -2.969 1.731 3.096 7.087 12.602 22.410 51.298 91.769 250 0 (0/5) 
Sea water 8 0.899 0.804 -0.642 0.008 0.057 0.911 6.288 43.394 698.788 4920.112 250 12.5 (1/8) 
WWTPs influent 5 0.873 3.844 -11.356 223.370 335.98 600.826 899.942 1347.969 2410.549 3625.799 250 100 (5/5) 
WWTPs effluent 6 0.682 1.392 -3.259 4.677 14.441 71.893 219.399 669.550 3333.369 10291.118 250 66.66 (4/6) 
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Clarithromycin River water 20 0.951 1.476 -1.497 0.274 0.794 3.608 10.333 29.594 134.471 389.354 250 0 (0/20) 
Lake water 5 0.879 1.586 -1.577 0.337 0.906 3.707 9.870 26.279 107.506 289.153 250 0 (0/5) 
Sea water 9 0.846 1.155 -0.283 0.017 0.066 0.458 1.758 6.745 46.681 181.625 250 0 (0/9) 
WWTPs influent 5 0.949 0.729 -1.551 0.086 0.743 15.935 134.144 1129.271 24203.992 208315.394 250 40 (2/5) 
WWTPs effluent 6 0.754 0.968 -1.916 0.377 1.906 19.167 95.354 474.379 4770.543 24131.859 250 33.33 (2/6) 
Erythromycin River water 42 0.944 1.261 -2.574 1.572 5.455 32.089 109.961 376.810 2216.365 7692.735 1000 14.28 (6/42) 
Lake water 13 0.982 0.938 -1.510 0.135 0.718 7.776 40.720 213.246 2308.784 12300.510 1000 15.38 (2/13) 
Drinking water 7 0.985 1.332 -1.659 0.315 1.025 5.484 17.599 56.477 302.253 981.755 1000 0 (0/7) 
Ground water 7 0.933 1.082 -1.740 0.287 1.224 9.655 40.563 170.414 1343.787 5730.300 1000 0 (0/7) 
Sea water 11 0.968 1.034 -0.829 0.036 0.163 1.411 6.335 28.448 246.893 1126.143 1000 0 (0/11) 
Other water 
compartments 
5 0.911 0.694 -1.272 0.030 0.290 7.260 68.054 637.882 15957.289 153087.348 1000 20 (1/5) 
WWTPs influent 14 0.648 0.657 -1.507 0.057 0.617 18.499 196.680 2091.126 62710.736 683319.567 1000 21.42 (3/14) 
WWTPs effluent 21 0.887 1.094 -2.299 0.944 3.962 30.544 126.317 522.394 4027.032 16901.416 1000 4.76 (1/21) 
Roxithromycin River water 39 0.936 1.209 -1.781 0.354 1.296 8.227 29.725 107.401 681.751 2496.376 1000 2.56 (1/39) 
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Lake water 12 0.915 1.258 -1.155 0.117 0.408 2.410 8.282 28.463 168.128 585.285 1000 0 (0/12) 
Drinking water 6 0.941 1.844 -1.608 0.408 0.955 3.208 7.448 17.290 58.079 136.017 1000 0 (0/6) 
Sea water 14 0.956 0.858 -0.930 0.024 0.147 1.985 12.132 74.137 1002.293 6241.331 1000 7.14 (1/14) 
WWTPs influent 10 0.822 1.091 -2.585 1.726 7.273 56.384 234.092 971.889 7534.297 31746.346 1000 20 (2/10) 
WWTPs effluent 15 0.925 1.068 -2.242 0.834 3.623 29.357 125.676 538.017 4358.891 18944.331 1000 13.33 (2/15) 
Tylosin River water 7 0.930 1.286 -1.351 0.174 0.591 3.358 11.234 37.586 213.595 723.642 4000 0 (0/7) 
Drinking water 7 0.822 1.695 -0.467 0.080 0.202 0.754 1.886 4.715 17.617 44.462 4000 0 (0/7) 
WWTPs effluent 7 0.892 1.181 -1.364 0.153 0.578 3.836 14.287 53.220 352.953 1332.801 4000 0 (0/7) 
Tetracycline River water 31 0.943 1.060 -1.850 0.355 1.561 12.852 55.627 240.765 1981.672 8708.650 1000 9.67 (3/31) 
Lake water 8 0.849 1.329 -2.055 0.625 2.035 10.933 35.178 113.186 608.048 1980.274 1000 0 (0/8) 
Ground water 6 0.939 1.771 -2.859 1.999 4.848 17.119 41.147 98.900 349.231 847.073 1000 0 (0/6) 
Sea water 9 0.906 1.138 -1.908 0.429 1.703 12.132 47.493 185.919 1324.389 5258.575 1000 11.11 (1/9) 
Other water 
compartments 
6 0.92 1.042 -2.182 0.727 3.277 27.974 124.179 551.255 4705.483 21214.336 1000 16.66 (1/6) 
Wastewater 5 0.907 0.574 -2.246 0.724 11.150 546.793 8182.613 122450.690 6004690.66 92419336.60 1000 80 (4/5) 
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WWTPs influent 8 0.973 2.583 -6.179 31.013 56.935 135.224 246.706 450.097 1069.004 1962.536 1000 0 (0/8) 
WWTPs effluent 13 0.751 1.061 -1.674 0.243 1.065 8.751 37.823 163.481 1342.898 5893.267 1000 7.69 (1/13) 
Chlortetracycline River water 26 0.909 1.162 -1.852 0.391 1.508 10.312 39.247 149.369 1021.740 3942.978 - - 
Lake water 8 0.961 1.138 -1.758 0.317 1.257 8.956 35.060 137.250 977.699 3882.021 - - 
Ground water 6 0.657 0.547 -1.193 0.008 0.149 8.870 151.701 2594.526 154181.485 2715866.149 - - 
Sea water 5 0.803 0.964 -1.101 0.054 0.273 2.770 13.871 69.470 705.336 3592.031 -  
Wastewater 5 0.963 0.809 -3.688 48.209 335.36 5308.62 36200.49 246857.972 3907581.70 27183099.76 - - 
WWTPs influent 7 0.844 1.633 -2.841 2.066 5.401 21.218 54.922 142.161 558.472 1459.917 - - 
WWTPs effluent 8 0.856 1.416 -2.103 0.695 2.106 10.206 30.561 91.517 443.393 1342.983 - - 
Oxytetracycline River water 35 0.931 1.199 -2.345 1.036 3.837 24.732 90.323 329.868 2126.430 7871.121 500 14.28 (5/35) 
Lake water 7 0.846 1.077 -1.779 0.310 1.332 10.606 44.855 189.705 1510.308 6483.902 500 14.28 (1/7) 
Drinking water 7 0.887 1.877 -2.942 2.128 4.910 16.145 36.931 84.477 277.789 640.902 500 0 (0/7) 
Ground water 6 0.684 0.669 -1.403 0.042 0.435 12.273 125.072 1274.576 35961.270 375414.482 500 16.66 (1/6) 





5 0.959 0.846 -1.876 0.294 1.876 26.316 165.004 1034.578 14513.278 92750.076 500 40 (2/5) 
Wastewater 5 0.967 0.885 -4.439 243.881 1436.2 17934.2 103709.6 599728.268 7488776.64 44102262.98 500 100 (5/5) 
WWTPs influent 8 0.969 1.748 -4.680 22.207 54.495 195.651 475.714 1156.669 4152.765 10190.797 500 50 (4/8) 
WWTPs effluent 13 0.966 1.406 -2.657 1.719 5.247 25.706 77.582 234.143 1147.202 3502.226 500 23.07 (3/13) 
Doxycycline River water 15 0.961 1.858 -2.023 0.687 1.598 5.318 12.269 28.302 94.208 219.218 2000 0 (0/15) 
Lake water 5 0.677 1.245 -2.271 0.903 3.184 19.157 66.695 232.196 1397.217 4927.753 2000 0 (0/5) 
Drinking water 5 0.800 1.226 -1.987 0.529 1.901 11.764 41.756 148.208 916.981 3297.830 2000 0 (0/5) 
WWTPs effluent 6 0.809 0.503 -1.017 0.002 0.056 4.797 105.164 2305.699 195864.406 4434195.725 2000 16.66 (1/6) 
Penicillin Drinking water 7 0.925 0.950 -1.421 0.111 0.581 6.107 31.318 160.612 1687.386 8801.906 64 57.14 (4/7) 
Lincomycin River water 10 0.968 1.411 -2.747 1.987 6.041 29.432 88.480 265.992 1295.932 3940.660 2000 0 (0/10) 
Lake water 7 0.917 0.911 -1.271 0.069 0.389 4.516 24.841 136.633 1587.514 8887.717 2000 0 (0/7) 
Drinking water 6 0.962 1.540 -1.536 0.307 0.850 3.626 9.940 27.251 116.276 322.120 2000 0 (0/6) 
Sulfamethoxazole River water 55 0.956 1.561 -2.907 2.355 6.435 26.926 72.823 196.950 824.111 2251.962 16000 0 (0/55) 
Lake water 17 0.979 1.292 -2.474 1.301 4.383 24.706 82.198 273.471 1541.584 5193.254 16000 0 (0/17) 
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Drinking water 11 0.900 1.846 -2.486 1.220 2.855 9.579 22.218 51.532 172.875 404.488 16000 0 (0/11) 
Ground water 7 0.936 1.147 -1.443 0.170 0.667 4.678 18.116 70.164 492.168 1933.155 16000 0 (0/7) 
Sea water 16 0.945 1.338 -1.615 0.294 0.950 5.046 16.107 51.420 273.126 882.472 16000 0 (0/16) 
Other water 
compartments 
8 0.948 1.601 -2.373 1.069 2.850 11.506 30.353 80.074 323.288 861.505 16000 0 (0/8) 
Wastewater 6 0.956 0.468 -1.176 0.003 0.100 11.792 325.702 8995.761 1065283.04 30454347.81 16000 33.33 (2/6) 
WWTPs influent 19 0.948 1.047 -2.482 1.408 6.303 53.256 234.738 1034.652 8741.752 39129.145 16000 0 (0/19) 
WWTPs effluent 25 0.981 1.173 -2.472 1.331 5.072 34.073 128.61 481.315 3233.547 12321.488 16000 0 (0/25) 
Sulfacetamide River water 6 0.994 1.333 -1.126 0.126 0.408 2.181 6.994 22.424 119.856 388.963 - - 
Sulfachloropyridazine River water 11 0.910 1.839 -1.414 0.319 0.749 2.524 5.873 13.667 46.060 108.119 - - 
WWTPs effluent 6 0.965 1.121 -1.019 0.068 0.277 2.029 8.110 32.411 237.859 964.391 - - 
Sulfadiazine River water 49 0.974 1.349 -2.203 0.810 2.593 13.585 42.960 135.848 711.828 2278.031 - - 
Lake water 14 0.924 1.089 -1.659 0.244 1.030 8.018 33.375 138.926 1081.040 4567.094 - - 
Drinking water 9 0.908 1.992 -2.533 1.270 2.792 8.570 18.689 40.755 125.117 275.063 - - 





8 0.983 1.136 -1.766 0.321 1.278 9.138 35.857 140.708 1005.801 4003.307 - - 
WWTPs influent 13 0.974 0.829 -1.644 0.134 0.893 13.220 86.072 560.376 8298.568 55089.777 - - 
WWTPs effluent 20 0.917 0.805 -1.430 0.077 0.541 8.680 59.758 411.408 6602.280 46373.583 - - 
Sulfadimethoxine River water 9 0.958 2.033 -0.943 0.209 0.452 1.355 2.910 6.246 18.747 40.564 - - 
Sea water 5 0.948 1.204 0.0914 0.010 0.036 0.231 0.840 3.050 19.509 71.824 - - 
WWTPs influent 5 0.984 1.166 -0.837 0.053 0.203 1.378 5.222 19.784 134.437 516.407 - - 
WWTP effluent 5 0.885 1.109 0.0222 0.008 0.031 0.235 0.955 3.874 29.051 119.586 - - 
Sulfadimidine River water 9 0.964 1.234 -1.975 0.519 1.852 11.321 39.855 140.305 857.888 3059.815 - - 
Sulfamerazine River water 9 0.847 0.678 -0.599 0.003 0.029 0.774 7.647 75.562 2039.476 20638.227 - - 
WWTPs influent 7 0.976 1.541 -1.162 0.176 0.486 2.072 5.676 15.551 66.290 183.523 - - 
WWTPs effluent 10 0.880 0.966 -0.380 0.010 0.049 0.496 2.474 12.348 124.773 633.290 - - 
Sulfameter River water 11 0.946 1.103 -1.112 0.079 0.329 2.493 10.190 41.655 315.801 1309.994 - - 
Sulfamethazine River water 38 0.968 1.192 -2.053 0.590 2.200 14.337 52.761 194.161 1265.395 4720.082 - - 
Lake water 12 0.789 1.417 -0.865 0.093 0.282 1.363 4.078 12.202 59.053 178.725 - - 
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Drinking water 9 0.953 1.500 -1.773 0.428 1.217 5.339 15.205 42.821 189.919 540.628 - - 
Ground water 5 0.873 1.314 -0.912 0.084 0.277 1.516 4.944 16.120 88.279 291.404 - - 
Sea water 9 0.957 1.226 -0.952 0.076 0.272 1.684 5.977 21.216 131.266 472.084 - - 
WWTPs influent 13 0.853 1.197 -1.621 0.257 0.955 6.176 22.606 82.737 535.015 1984.727 - - 
WWTPs effluent 19 0.978 0.975 -1.154 0.063 0.314 3.103 15.261 75.054 742.368 3711.826 - - 
Sulfamethizole WWTPs influent 5 0.891 0.796 -0.512 0.005 0.038 0.625 4.398 30.943 512.407 3679.287 - - 
WWTPs effluent 5 0.970 1.599 -0.199 0.047 0.125 0.504 1.332 3.518 14.228 37.960 - - 
Sulfamonomethoxine River water 12 0.986 1.591 -2.622 1.534 4.113 16.752 44.465 118.021 480.694 1288.880 - - 
Lake water 6 0.818 1.206 -1.800 0.366 1.345 8.575 31.084 112.672 718.505 2639.463 - - 
Drinking water 6 0.895 1.368 -2.177 0.778 2.449 2.541 39.028 121.457 621.946 1958.488 - - 
Sulfapyridine River water 21 0.991 1.272 -1.630 0.284 0.973 5.639 19.118 64.820 375.466 1289.248 - - 
Lake water 8 0.962 1.184 -0.692 0.042 0.157 1.035 3.841 14.260 94.123 354.226 - - 
Drinking water 6 0.951 2.290 -0.769 0.209 0.415 1.100 2.167 4.269 11.326 22.474 - - 
WWTPs effluent 6 0.929 0.920 -1.661 0.189 1.041 11.811 63.890 345.602 3920.299 21581.110 - - 
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Sulfaquinoxaline River water 12 0.969 1.884 -2.014 0.683 1.570 5.140 11.722 26.731 87.512 201.277 - - 
Sulfathiazole River water 16 0.876 1.275 -1.148 0.119 0.408 2.352 7.950 26.878 155.051 530.858 - - 
Lake water 6 0.950 1.953 -1.838 0.562 1.256 3.942 8.732 19.341 60.720 135.607 - - 
WWTPs effluent 6 0.844 0.997 -0.454 0.013 0.064 0.601 2.853 13.548 127.400 614.772 - - 
Trimethoprim River water 38 0.901 1.124 -2.033 0.548 2.215 16.167 64.375 256.330 1871.164 7558.287 500 18.42 (7/38) 
Lake water 8 0.922 1.657 -1.384 0.270 0.696 2.680 6.843 17.470 67.284 173.459 500 0 (0/8) 
Drinking water 7 0.844 2.127 -2.022 0.719 1.504 4.301 8.926 18.524 52.961 110.753 500 0 (0/7) 
Sea water 10 0.992 1.226 -1.509 0.215 0.775 4.794 17.015 60.393 373.658 1343.824 500 0 (0/10) 
Other water 
compartments 
5 0.727 1.510 -2.102 0.710 2.008 8.818 24.663 68.982 302.942 856.408 500 0 (0/5) 
WWTPs influent 15 0.909 1.255 -2.814 2.447 8.543 50.674 174.675 602.106 3571.671 12470.812 500 40 (6/15) 
WWTPs effluent 21 0.931 0.994 -1.946 0.414 2.009 19.019 90.729 432.820 4097.593 19867.201 500 23.80 (5/21) 
Thiamphenicol River water 7 0.949 0.944 -1.084 0.255 0.618 2.715 14.070 72.913 777.562 4098.799 1000 0 (0/7) 
Florfenicol River water 12 0.952 1.065 -1.996 0.490 2.137 17.412 74.848 321.738 2622.056 11443.071 2000 8.33 (1/12) 
Lake water 10 0.898 1.334 -2.942 2.894 9.384 50.094 160.471 514.058 2744.233 8897.874 2000 0 (0/10) 
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Abbreviations: n: the total number of data points or studies, a: slope, b: intercept, PNEC: predicted not effect concentration for the development of antibiotic resistance, 












Sea water 5 0.912 1.517 -1.399 0.245 0.689 3.003 8.360 23.272 101.507 285.584 2000 0 (0/5) 
Chloramphenicol River water 16 0.914 1.396 -1.543 0.275 0.845 4.189 12.744 38.767 192.116 591.206 8000 0 (0/16) 
WWTPs influent 5 0.943 5.905 -9.76 18.150 23.675 34.563 44.961 58.487 85.387 111.378 8000 0 (0/5) 
WWTPs effluent 8 0,967 1.609 -1.657 0.384 1.018 4.080 10.711 28.121 112.750 298.997 8000 0 (0/8) 
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Appendix 5. Values of equations for regression analysis and values corresponding to various centiles for measured 
environmental concentration distributions of the maximum reported antibiotic concentrations (ng/L) in aquatic 
compartments of India, and percentage exceeding a predicted no effect concentration (PNEC) for the development of 
antibiotic resistance (Study III) 
















1% 5% 25% 50% 75% 95% 99% 
Ofloxacin Waste water 3 1.000 1.014 -3.933 38.412 180.53 1635.012 7563.072 34984.486 316841.340 1489110.402 500 100 (3/3) 
Levofloxacin Waste water 3 0.989 1.219 -4.929 136.48 494.46 3091.465 11052.95 39517.754 247072.813 895127.807 250 100 (3/3) 
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Appendix 6. Ranking of antibiotics in various aquatic environmental compartments of China, based on descending 
orders of overall, criterion, and attribute risk utility scores (Study IV) 
Priority Overall risk Environmental risk Human health risk 
Resistance risk on 
environment 
Ecotoxicity risk Overall environmental 
risk 
Resistance risk on 
human health 
Toxicity risk on human 
health 
Overall human health 
risk 
1 Ciprofloxacin Ciprofloxacin Norfloxacin Ciprofloxacin Ciprofloxacin Ciprofloxacin Ciprofloxacin 
2 Norfloxacin Oxytetracyclin Tetracyclin Oxytetracyclin Penicillin Norfloxacin Norfloxacin 
3 Oxytetracyclin Enrofloxacin Roxithromycin Norfloxacin Enrofloxacin Oxytetracyclin Penicillin 
4 Enrofloxacin Azithromycin Azithromycin Azithromycin Norfloxacin Erythromycin Oxytetracyclin 
5 Tetracyclin Norfloxacin Oxytetracyclin Enrofloxacin Oxytetracyclin Penicillin Erythromycin 
6 Erythromycin Ofloxacin Chlortetracyclin Tetracyclin Ofloxacin Doxycycline Enrofloxacin 
7 Penicillin Tetracyclin Erythromycin Ofloxacin Azithromycin Sulfamethoxazole Doxycycline 
8 Ofloxacin Trimethoprim Sulfamethoxazole Roxithromycin Tetracyclin Tetracyclin Sulfamethoxazole 
9 Azithromycin Erythromycin Clarithromycin Erythromycin Roxithromycin Sulfamonomethoxine Ofloxacin 
10 Sulfamethoxazole Clarithromycin Ofloxacin Clarithromycin Erythromycin Ofloxacin Tetracyclin 
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11 Chlortetracyclin Roxithromycin Lincomycin Chlortetracyclin Clarithromycin Lomefloxacin Sulfamonomethoxine 
12 Roxithromycin Sulfamethoxazole Ciprofloxacin Sulfamethoxazole Chlortetracyclin Enrofloxacin Lomefloxacin 
13 Doxycycline Moxifloxacin Enrofloxacin Trimethoprim Sulfamethoxazole Sulfamethazine Chlortetracyclin 
14 Clarithromycin Doxycycline Moxifloxacin Lincomycin Trimethoprim Sulfadiazine Sulfamethazine 
15 Sulfamonomethoxine Florfenicol Tylosin Moxifloxacin Lincomycin Chlortetracyclin Sulfadiazine 
16 Lomefloxacin Penicillin Lomefloxacin Doxycycline Moxifloxacin Azithromycin Azithromycin 
17 Trimethoprim Chlortetracyclin Sulfadiazine Florfenicol Doxycycline Roxithromycin Roxithromycin 
18 Lincomycin Sulfamonomethoxine Trimethoprim Tylosin Florfenicol Clarithromycin Clarithromycin 
19 Sulfadiazine Lomefloxacin Doxycycline Lomefloxacin Tylosin Trimethoprim Trimethoprim 
20 Sulfamethazine Lincomycin Florfenicol Sulfadiazine Lomefloxacin Lincomycin Lincomycin 
21 Moxifloxacin Sulfadiazine Penicillin Penicillin Sulfadiazine Moxifloxacin Moxifloxacin 
22 Florfenicol Sulfamethazine Sulfamonomethoxine Sulfamonomethoxine Sulfamonomethoxine Florfenicol Florfenicol 
23 Tylosin Tylosin Sulfamethazine Sulfamethazine Sulfamethazine Tylosin Tylosin 
24 Fleroxacin Fleroxacin Fleroxacin Fleroxacin Fleroxacin Fleroxacin Fleroxacin 
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25 Enoxacin Enoxacin Enoxacin Enoxacin Enoxacin Enoxacin Enoxacin 
26 Nalidixic acid Nalidixic acid Nalidixic acid Nalidixic acid Nalidixic acid Nalidixic acid Nalidixic acid 
27 Sarafloxacin Sarafloxacin Sarafloxacin Sarafloxacin Sarafloxacin Sarafloxacin Sarafloxacin 
28 Difloxacin Difloxacin Difloxacin Difloxacin Difloxacin Difloxacin Difloxacin 
29 Flumequine Flumequine Flumequine Flumequine Flumequine Flumequine Flumequine 
30 Sulfacetamide Sulfacetamide Sulfacetamide Sulfacetamide Sulfacetamide Sulfacetamide Sulfacetamide 
31 Sulfachloropyridazine Sulfachloropyridazine Sulfachloropyridazine Sulfachloropyridazine Sulfachloropyridazine Sulfachloropyridazine Sulfachloropyridazine 
32 Sulfadimethoxine Sulfadimethoxine Sulfadimethoxine Sulfadimethoxine Sulfadimethoxine Sulfadimethoxine Sulfadimethoxine 
33 Sulfadimidine Sulfadimidine Sulfadimidine Sulfadimidine Sulfadimidine Sulfadimidine Sulfadimidine 
34 Sulfamerazine Sulfamerazine Sulfamerazine Sulfamerazine Sulfamerazine Sulfamerazine Sulfamerazine 
35 Sulfameter Sulfameter Sulfameter Sulfameter Sulfameter Sulfameter Sulfameter 
36 Sulfamethizole Sulfamethizole Sulfamethizole Sulfamethizole Sulfamethizole Sulfamethizole Sulfamethizole 
37 Sulfapyridine Sulfapyridine Sulfapyridine Sulfapyridine Sulfapyridine Sulfapyridine Sulfapyridine 
38 Sulfaquinoxaline Sulfaquinoxaline Sulfaquinoxaline Sulfaquinoxaline Sulfaquinoxaline Sulfaquinoxaline Sulfaquinoxaline 
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39 Sulfathiazole Sulfathiazole Sulfathiazole Sulfathiazole Sulfathiazole Sulfathiazole Sulfathiazole 
40 Thiamphenicol Thiamphenicol Thiamphenicol Thiamphenicol Thiamphenicol Thiamphenicol Thiamphenicol 
















Appendix 7. Ranking of data gap of antibiotics in various aquatic environmental compartments of China, based on 
descending orders of overall, criterion, and attribute data gap scores (Study IV) 
Priority Overall risk Environmental risk Human health risk 
Resistance risk on 
environment 
Ecotoxicity risk Overall environmental 
risk 
Resistance risk on 
human health 
Toxicity risk on human 
health 
Overall human health 
risk 
1 Fleroxacin Fleroxacin Fleroxacin Fleroxacin Fleroxacin Fleroxacin Fleroxacin 
2 Enoxacin Enoxacin Enoxacin Enoxacin Enoxacin Enoxacin Enoxacin 
3 Sarafloxacin Sarafloxacin Sarafloxacin Sarafloxacin Sarafloxacin Sarafloxacin Sarafloxacin 
4 Difloxacin Difloxacin Difloxacin Difloxacin Difloxacin Difloxacin Difloxacin 
5 Sulfacetamide Sulfacetamide Sulfacetamide Sulfacetamide Sulfacetamide Sulfacetamide Sulfacetamide 
6 Sulfachloropyridazine Sulfachloropyridazine Sulfachloropyridazine Sulfachloropyridazine Sulfachloropyridazine Sulfachloropyridazine Sulfachloropyridazine 
7 Sulfamerazine Sulfamerazine Sulfamerazine Sulfamerazine Sulfamerazine Sulfamerazine Sulfamerazine 
8 Sulfameter Sulfameter Sulfameter Sulfameter Sulfameter Sulfameter Sulfameter 
9 Sulfamethizole Sulfamethizole Sulfamethizole Sulfamethizole Sulfamethizole Sulfamethizole Sulfamethizole 
10 Sulfaquinoxaline Sulfaquinoxaline Sulfaquinoxaline Sulfaquinoxaline Sulfaquinoxaline Sulfaquinoxaline Sulfaquinoxaline 
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11 Sulfadimidine Sulfadimidine Sulfapyridine Sulfapyridine Sulfapyridine Sulfadimidine Sulfadimidine 
12 Nalidixic acid Sulfathiazole Penicillin Penicillin Sulfamethazine Nalidixic acid Nalidixic acid 
13 Flumequine Sulfadimethoxine Sulfamethazine Sulfamethazine Sulfadimidine Flumequine Flumequine 
14 Sulfathiazole Sulfapyridine Nalidixic acid Sulfadimidine Nalidixic acid Sulfathiazole Sulfathiazole 
15 Moxifloxacin Sulfamonomethoxine Doxycycline Nalidixic acid Sulfamonomethoxine Moxifloxacin Moxifloxacin 
16 Thiamphenicol Lomefloxacin Flumequine Sulfamonomethoxine Flumequine Thiamphenicol Thiamphenicol 
17 Sulfadimethoxine Sulfadiazine Moxifloxacin Flumequine Sulfathiazole Sulfadimethoxine Sulfadimethoxine 
18 Sulfapyridine Chlortetracyclin Sulfadimidine Sulfathiazole Lomefloxacin Florfenicol Florfenicol 
19 Florfenicol Penicillin Thiamphenicol Lomefloxacin Moxifloxacin Chloramphenicol Chloramphenicol 
20 Chloramphenicol Sulfamethazine Tylosin Moxifloxacin Thiamphenicol Azithromycin Azithromycin 
21 Sulfamonomethoxine Nalidixic acid Sulfamonomethoxine Thiamphenicol Sulfadimethoxine Clarithromycin Clarithromycin 
22 Lomefloxacin Flumequine Lincomycin Sulfadimethoxine Sulfadiazine Sulfapyridine Sulfapyridine 
23 Sulfadiazine Moxifloxacin Sulfathiazole Tylosin Chlortetracyclin Sulfamonomethoxine Sulfamonomethoxine 
24 Azithromycin Thiamphenicol Lomefloxacin Doxycycline Florfenicol Lomefloxacin Lomefloxacin 
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25 Clarithromycin Tylosin Florfenicol Lincomycin Chloramphenicol Sulfadiazine Sulfadiazine 
26 Chlortetracyclin Lincomycin Chloramphenicol Sulfadiazine Azithromycin Chlortetracyclin Chlortetracyclin 
27 Penicillin Florfenicol Sulfadimethoxine Chlortetracyclin Clarithromycin Penicillin Penicillin 
28 Sulfamethazine Chloramphenicol Azithromycin Florfenicol Penicillin Tylosin Tylosin 
29 Tylosin Doxycycline Clarithromycin Chloramphenicol Tylosin Doxycycline Doxycycline 
30 Doxycycline Azithromycin Roxithromycin Azithromycin Doxycycline Lincomycin Lincomycin 
31 Lincomycin Clarithromycin Trimethoprim Clarithromycin Lincomycin Roxithromycin Roxithromycin 
32 Roxithromycin Roxithromycin Norfloxacin Roxithromycin Roxithromycin Trimethoprim Trimethoprim 
33 Trimethoprim Trimethoprim Sulfadiazine Trimethoprim Trimethoprim Enrofloxacin Enrofloxacin 
34 Enrofloxacin Norfloxacin Ofloxacin Norfloxacin Enrofloxacin Tetracyclin Tetracyclin 
35 Tetracyclin Ofloxacin Erythromycin Ofloxacin Tetracyclin Sulfamethazine Sulfamethazine 
36 Norfloxacin Erythromycin Chlortetracyclin Erythromycin Norfloxacin Norfloxacin Norfloxacin 
37 Ofloxacin Enrofloxacin Enrofloxacin Enrofloxacin Ofloxacin Ofloxacin Ofloxacin 
38 Erythromycin Tetracyclin Tetracyclin Tetracyclin Erythromycin Erythromycin Erythromycin 
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39 Ciprofloxacin Ciprofloxacin Ciprofloxacin Ciprofloxacin Ciprofloxacin Ciprofloxacin Ciprofloxacin 
40 Oxytetracyclin Oxytetracyclin Oxytetracyclin Oxytetracyclin Oxytetracyclin Oxytetracyclin Oxytetracyclin 
41 Sulfamethoxazole Sulfamethoxazole Sulfamethoxazole Sulfamethoxazole Sulfamethoxazole Sulfamethoxazole Sulfamethoxazole 
 
 
 
 
 
 
 
